REVVITY, INC., 10-K filed on 2/27/2024
Annual Report
v3.24.0.1
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2023
Feb. 23, 2024
Jun. 30, 2023
Jan. 01, 2023
Entity Listings [Line Items]        
Document Annual Report true      
Entity Well-known Seasoned Issuer Yes      
Entity Voluntary Filers No      
Entity Current Reporting Status Yes      
Entity Interactive Data Current Yes      
Entity Public Float     $ 14,697,780,722  
ICFR Auditor Attestation Flag true      
Entity Shell Company false      
Document Financial Statement Error Correction [Flag] false      
Sale of Stock, Price Per Share     $ 118.79  
Common stock, par value $ 1     $ 1
Document Type 10-K      
Document Period End Date Dec. 31, 2023      
Document Transition Report false      
Entity File Number 001-5075      
Entity Registrant Name REVVITY, INC.      
Entity Incorporation, State or Country Code MA      
Entity Tax Identification Number 04-2052042      
Entity Address, Address Line One 940 Winter Street,      
Entity Address, City or Town Waltham,      
Entity Address, State or Province MA      
Entity Address, Postal Zip Code 02451      
City Area Code 781      
Local Phone Number 663-6900      
Entity Current Reporting Status Yes      
Entity Interactive Data Current Yes      
Entity Filer Category Large Accelerated Filer      
Entity Small Business false      
Entity Emerging Growth Company false      
Entity Common Stock, Shares Outstanding   123,529,821    
Entity Central Index Key 0000031791      
Document Fiscal Year Focus 2023      
Document Fiscal Period Focus FY      
Amendment Flag false      
Current Fiscal Year End Date --12-31      
PKI [Member]        
Entity Listings [Line Items]        
Trading Symbol RVTY      
Trading Symbol RVTY      
PKI 21A [Member]        
Entity Listings [Line Items]        
Trading Symbol RVTY 26      
Trading Symbol RVTY 26      
Common stock, $1 par value per share [Member]        
Entity Listings [Line Items]        
Title of 12(b) Security Common Stock, $1 par value per share      
Title of 12(b) Security Common Stock, $1 par value per share      
1.875% Notes due 2026 [Member]        
Entity Listings [Line Items]        
Title of 12(b) Security 1.875% Notes due 2026      
Title of 12(b) Security 1.875% Notes due 2026      
NEW YORK STOCK EXCHANGE, INC. [Member]        
Entity Listings [Line Items]        
Security Exchange Name NYSE      
Security Exchange Name NYSE      
v3.24.0.1
Audit Information
 12 Months Ended
Dec. 31, 2023
Audit Information [Abstract]  
Auditor Name DELOITTE & TOUCHE LLP
Auditor Location Boston, Massachusetts
Auditor Firm ID 34
v3.24.0.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2023
Feb. 23, 2024
Jun. 30, 2023
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Document Transition Report false    
Entity File Number 001-5075    
Entity Registrant Name REVVITY, INC.    
Entity Central Index Key 0000031791    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Amendment Flag false    
Entity Incorporation, State or Country Code MA    
Entity Tax Identification Number 04-2052042    
Entity Address, Address Line One 940 Winter Street,    
Entity Address, City or Town Waltham,    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02451    
City Area Code 781    
Local Phone Number 663-6900    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 14,697,780,722
Entity Common Stock, Shares Outstanding   123,529,821  
Documents Incorporated by Reference
Portions of Revvity, Inc.’s Definitive Proxy Statement for its Annual Meeting of Shareholders to be held on April 23, 2024 are incorporated by reference into Part III of this Form 10-K.
    
Common stock, $1 par value per share [Member]      
Entity Information [Line Items]      
Title of 12(b) Security Common Stock, $1 par value per share    
1.875% Notes due 2026 [Member]      
Entity Information [Line Items]      
Title of 12(b) Security 1.875% Notes due 2026    
NEW YORK STOCK EXCHANGE, INC. [Member]      
Entity Information [Line Items]      
Security Exchange Name NYSE    
PKI [Member]      
Entity Information [Line Items]      
Trading Symbol RVTY    
PKI 21A [Member]      
Entity Information [Line Items]      
Trading Symbol RVTY 26    
v3.24.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Revenue      
Revenue from Contract with Customer, Excluding Assessed Tax $ 2,750,571 $ 3,311,822 $ 3,827,808
Selling, general and administrative expenses 1,022,551 1,025,514 975,193
Research and development expenses 216,578 221,617 200,337
Operating income from continuing operations 300,562 742,699 1,258,457
Interest and other expense, net 117,586 90,862 54,875
Income from continuing operations before income taxes 182,976 651,837 1,203,582
Provision for income taxes 3,473 139,161 314,146
Income from continuing operations 179,503 512,676 889,436
Income from discontinued operations and dispositions 513,591 56,503 53,721
Net income $ 693,094 $ 569,179 $ 943,157
Basic earnings per share:      
Income from continuing operations $ 1.44 $ 4.06 $ 7.66
Income from discontinued operations and dispositions 4.12 0.45 0.46
Net income 5.56 4.51 8.12
Diluted earnings per share:      
Income from continuing operations 1.44 4.06 7.62
Income from discontinued operations and dispositions 4.11 0.45 0.46
Net income $ 5.55 $ 4.50 $ 8.08
Product [Member]      
Revenue      
Revenue from Contract with Customer, Excluding Assessed Tax $ 2,415,893 $ 2,634,582 $ 2,735,068
Cost of Goods and Services Sold 1,077,744 1,150,402 1,129,223
Service [Member]      
Revenue      
Revenue from Contract with Customer, Excluding Assessed Tax 334,678 677,240 1,092,740
Cost of Goods and Services Sold $ 133,136 $ 171,590 $ 264,598
v3.24.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Net income $ 693,094 $ 569,179 $ 943,157
Other comprehensive income (loss)      
Foreign currency translation adjustments, net of income taxes, recognized in other comprehensive income 80,172 (284,854) (130,873)
Foreign currency translation adjustments, net of income taxes, recognized in discontinued operations 90,814 0 0
Net foreign currency translation adjustments, net of income taxes 170,986 (284,854) (130,873)
Unrecognized prior service credit (cost), net of tax 0 44 (95)
Unrealized (losses) gains on securities, net of tax (181) 5 237
Other comprehensive income (loss) 170,805 (284,805) (130,731)
Comprehensive income $ 863,899 $ 284,374 $ 812,426
v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Current assets:    
Cash and cash equivalents $ 913,163 $ 454,358
Marketable Securities, Current 689,916 0
Accounts receivable, net 632,811 612,780
Inventories 428,062 405,462
Other current assets 337,139 122,254
Current assets of discontinued operations 0 1,693,704
Total current assets 3,001,091 3,288,558
Property, plant and equipment, net 509,654 482,950
Operating Lease, Right-of-Use Asset 155,083 188,351
Intangible assets, net 3,022,321 3,377,174
Beginning balance 6,533,550 6,481,768
Other assets, net 342,966 311,054
Total assets 13,564,665 14,129,855
Current liabilities:    
Current portion of long-term debt 721,872 470,929
Accounts payable 204,121 272,826
Accrued expenses and other current liabilities 524,470 527,863
Current liabilities of discontinued operations 0 272,865
Total current liabilities 1,450,463 1,544,483
Long-term debt 3,177,770 3,923,347
Long-term liabilities 930,946 1,109,181
Operating Lease, Liability, Noncurrent 132,747 169,968
Total liabilities 5,691,926 6,746,979
Commitments and contingencies (see Note 16)
Stockholders' equity:    
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding 0 0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 123,426,000 and 126,300,000 shares at December 31, 2023 and January 1, 2023, respectively 123,426 126,300
Capital in excess of par value 2,416,793 2,753,055
Retained earnings 5,609,212 4,951,018
Accumulated other comprehensive loss (276,692) (447,497)
Total stockholders' equity 7,872,739 7,382,876
Total liabilities and stockholders' equity $ 13,564,665 $ 14,129,855
v3.24.0.1
Consolidated Balance Sheet Parenthetical - $ / shares
Dec. 31, 2023
Jan. 01, 2023
Balance Sheet Parenthetical [Abstract]    
Preferred stock, par value $ 1 $ 1
Preferred stock, authorized 1,000,000 1,000,000
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value $ 1 $ 1
Common stock, authorized 300,000,000 300,000,000
Common stock, issued 123,426,000 126,300,000
Common stock, outstanding 123,426,000 126,300,000
v3.24.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock Amount [Member]
Common Stock Amount [Member]
Net Income [Member]
Common Stock Amount [Member]
Other comprehensive loss [Member]
Common Stock Amount [Member]
Dividends [Member]
Common Stock Amount [Member]
Issuance of common stock for business combination, net of issuance costs [Member]
Common Stock Amount [Member]
Exercise of employee stock options and related income tax benefits [Member]
Common Stock Amount [Member]
Purchases of common stock [Member]
Common Stock Amount [Member]
Issuance of common stock for employee stock purchase plans [Member]
Common Stock Amount [Member]
Issuance of common stock for long-term incentive program [Member]
Common Stock Amount [Member]
Stock compensation [Member]
Capital In Excess of Par Value [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Common stock, outstanding   112,090,000                        
Beginning Balance at Jan. 03, 2021 $ 3,735,492 $ 112,090                   $ 148,101 $ 3,507,262 $ (31,961)
Net income 943,157                       943,157  
Other comprehensive income (loss) (130,731)                          
Dividends 33,245                       33,245 0
Exercise of employee stock options and related income tax benefits 25,120 358                   24,762    
Issuance of common stock for employee benefit plans 3,628 21                   3,607    
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations 73,072 504                   72,568    
Issuance of common stock for long-term incentive program 26,501 209                   26,292    
Stock compensation 6,251 0                   6,251 0 0
Ending Balance at Jan. 02, 2022 7,141,245 126,241                   2,760,522 4,417,174 (162,692)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (130,731)                          
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax (130,731)                         (130,731)
Stock Issued During Period, Value, Acquisitions (2,638,144) $ (14,067)                   (2,624,077) 0 0
Common stock, outstanding   126,241,000 0 0 0 14,067,000 358,000 (504,000) 21,000 209,000 0      
Net income 569,179                       569,179  
Other comprehensive income (loss) (284,805)                          
Dividends 35,335                       35,335  
Exercise of employee stock options and related income tax benefits 14,114 $ 195                   13,919    
Issuance of common stock for employee benefit plans 4,172 31                   4,141    
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations 80,638 493                   80,145    
Issuance of common stock for long-term incentive program 44,561 326                   44,235    
Stock compensation 10,383 0                   10,383 0 0
Ending Balance at Jan. 01, 2023 7,382,876 $ 126,300                   2,753,055 4,951,018 (447,497)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (284,805)                          
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax $ (284,805)                         (284,805)
Common stock, outstanding 126,300,000 126,300,000 0 0 0   195,000 (493,000) 31,000 326,000 0      
Net income $ 693,094                       693,094  
Other comprehensive income (loss) 170,805                          
Dividends 34,900                       34,900  
Exercise of employee stock options and related income tax benefits 4,344 $ 58                   4,286    
Issuance of common stock for employee benefit plans 3,132 29                   3,103    
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations 392,302 3,267                   389,035    
Issuance of common stock for long-term incentive program 35,192 306                   34,886    
Stock compensation 10,498 0                   10,498 0 0
Ending Balance at Dec. 31, 2023 7,872,739 $ 123,426                   $ 2,416,793 $ 5,609,212 (276,692)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 79,991                          
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax $ 170,805                         $ 170,805
Common stock, outstanding 123,426,000 123,426,000 0 0 0   58,000 (3,267,000) 29,000 306,000 0      
v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 914,373 $ 470,746 $ 619,337
Operating activities:      
Net income 693,094 569,179 943,157
Income (Loss) from discontinued operations and dispositions (513,591) (56,503) (53,721)
Income from continuing operations 179,503 512,676 889,436
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:      
Restructuring and other costs, net 26,601 (13,580) (14,358)
Depreciation and amortization 431,769 427,000 311,443
Stock-based compensation 41,410 51,518 29,675
Pension and other post-retirement expense (income) 23,089 (23,104) (28,509)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability 4,168 (1,377) 3,119
Deferred taxes (123,664) (105,923) (55,328)
Contingencies and Non-Cash Tax Matters 26,183 (1,488) 1,924
Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts 7,349 7,310 4,962
Gain on disposition of businesses and assets, net 0 (2,887) (1,970)
Amortization of acquired inventory revaluation 0 45,289 35,201
Asset Impairment Charges 0 0 3,868
Change in fair value of financial securities 33,921 15,754 (10,985)
Debt Extinguishment Income (3,685) (2,880) 0
Unrealized Foreign Exchange Loss 24,089 0 0
Changes in assets and liabilities which (used) provided cash, excluding effects from companies purchased and divested:      
Accounts receivable, net (8,997) 66,093 165,590
Inventories, net (14,109) (48,634) 32,280
Accounts payable (76,426) (43,804) (7,577)
Accrued expenses and other (291,814) (236,623) (57,303)
Net cash provided by operating activities of continuing operations 279,387 672,500 1,330,184
Net cash (used in) provided by operating activities of discontinued operations (188,115) 7,310 80,566
Net cash provided by operating activities 91,272 679,810 1,410,750
Investing activities:      
Capital expenditures (81,368) (85,632) (86,020)
Payments to Acquire Investments (6,300) (47,181) (23,130)
Payments to Acquire Intangible Assets (1,221,609) 0 0
Proceeds from Collection of Notes Receivable 0 8,890 0
Proceeds from Divestiture of Businesses 153 14,505 1,569
Proceeds from surrender of life insurance policies 550,000 0 0
Cash paid for acquisitions, net of cash acquired (2,086) (7,518) (3,982,216)
Net cash used in investing activities of continuing operations (761,210) (116,936) (4,089,797)
Net cash provided by (used in) investing activities of discontinued operations 2,074,734 (15,915) (22,961)
Net cash provided by (used in) investing activities 1,313,524 (132,851) (4,112,758)
Financing activities:      
Payments on revolving credit facility 0 (740,000) (1,559,133)
Proceeds from Long-term Lines of Credit 0 240,000 1,900,282
Payments of Senior Debt (523,808) (57,876) (339,605)
Proceeds from sale of senior debt 0 0 3,086,095
Payments of debt financing and equity issuance costs (15) 0 (30,983)
Proceeds from (Repayments of) Other Debt 6,323 (1,292) (13,670)
Settlement of cash flow hedges 0 (762) (4,482)
Settlement of swaps 0 0 14,314
Payments for acquisition-related contingent consideration (10,117) (5) (2,208)
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 4,344 14,114 25,120
Purchases of common stock (388,882) (80,638) (73,072)
Dividends paid (34,966) (35,344) (32,373)
Net cash (used in) provided by financing activities (947,121) (661,803) 2,941,657
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (14,048) (33,747) (22,926)
Net increase (decrease) in cash, cash equivalents and restricted cash 443,627 (148,591) 216,723
Cash and cash equivalents at beginning of year 454,358 603,320  
Restricted Cash, Current 1,210 1,040 1,018
Restricted Cash, Noncurrent 0 349 0
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents 0 14,999 14,999
Cash and cash equivalents at end of year 913,163 454,358 603,320
Supplemental disclosures of cash flow information      
Interest Paid, Excluding Capitalized Interest, Operating Activities 94,008 97,934 54,120
Income taxes 359,800 323,077 364,565
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]      
Consideration receivable from sale of Business 241,353 0 0
Equity issued for business combination, net of issuance costs $ 0 $ 0 $ 2,638,144
v3.24.0.1
Interest and Other Expense (Income), Net
 12 Months Ended
Dec. 31, 2023
Other Income and Expenses [Abstract]  
Interest and Other Expense (Income), Net Interest and Other Expense, Net
Interest and other expense, net, consisted of the following for the fiscal years ended:
 
December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Interest income$(72,131)$(3,589)$(2,241)
Interest expense including costs of bridge financing98,813 103,955 102,128 
Change in fair value of financial securities33,921 15,754 (10,985)
Other components of net periodic pension cost (credit)19,006 (33,158)(37,385)
Foreign exchange losses and other expense, net37,977 7,900 3,358 
Total interest and other expense, net$117,586 $90,862 $54,875 
v3.24.0.1
Interest and Other Expense (Income), Net
 12 Months Ended
Dec. 31, 2023
Other Income and Expenses [Abstract]  
Interest and Other Expense (Income), Net
Interest and other expense, net, consisted of the following for the fiscal years ended:
 
December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Interest income$(72,131)$(3,589)$(2,241)
Interest expense including costs of bridge financing98,813 103,955 102,128 
Change in fair value of financial securities33,921 15,754 (10,985)
Other components of net periodic pension cost (credit)19,006 (33,158)(37,385)
Foreign exchange losses and other expense, net37,977 7,900 3,358 
Total interest and other expense, net$117,586 $90,862 $54,875 
v3.24.0.1
Interest and Other Expense (Income), Net - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Change in fair value of financial securities $ 33,921 $ 15,754 $ (10,985)
Interest expense including costs of bridge financing 98,813 103,955 102,128
Interest income (72,131) (3,589) (2,241)
Interest expense including costs of bridge financing 98,813 103,955 102,128
Other components of net periodic pension (credit) cost 19,006 (33,158) (37,385)
Other expense, net 37,977 7,900 3,358
Total interest and other expense, net $ 117,586 $ 90,862 $ 54,875
v3.24.0.1
Business Combinations and Asset Purchases
 12 Months Ended
Dec. 31, 2023
Business Combinations [Abstract]  
Business Combinations and Asset Purchases Business Combinations
Acquisitions in fiscal year 2022
During fiscal year 2022, the Company completed the acquisition of two businesses for aggregate consideration of $13.3 million. Identifiable definite-lived intangible assets, such as core technology, acquired as part of these acquisitions had a weighted average amortization period of 5 years.
Acquisitions in fiscal year 2021
Acquisition of BioLegend, Inc. In fiscal year 2021, the Company completed the acquisition of BioLegend, Inc. (“BioLegend”) and paid an aggregate consideration of $5.7 billion, net of cash acquired of $292.4 million, reflecting working capital and other adjustments (the “Aggregate Consideration”). The Aggregate Consideration was paid in a combination of $3.3 billion in cash and shares of the Company’s common stock having a fair value of approximately $2.6 billion based on the $187.56 per share closing price of the Company's common stock on the New York Stock Exchange on September 17, 2021 (the “Stock Consideration”). The Stock Consideration consisted of 14,066,799 shares of the Company’s common stock. BioLegend is recognized as a leading, global provider of life science antibodies and reagents headquartered in San Diego, California, with approximately 700 employees. The operations for this acquisition is reported within the results of the Company’s Life Sciences segment from the acquisition date. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and is not tax deductible. Identifiable definite-lived intangible assets, such as core technology, trade names, customer relationships and clone library, acquired as part of this acquisition had a weighted-average amortization period of 16.3 years.
BioLegend’s revenue and net loss for the period from the acquisition date to January 2, 2022 were $91.7 million and $25.8 million, respectively. The net loss includes $47.0 million of amortization of acquired intangible assets. The following unaudited pro forma information presents the combined financial results for the Company and BioLegend as if the acquisition of BioLegend had been completed at the beginning of fiscal year 2020:
January 2,
2022
(In thousands, except per share data)
Pro Forma Statement of Operations Information:
Revenue$4,056,122 
Income from continuing operations947,387 
Basic earnings per share:
Income from continuing operations$7.27 
Diluted earnings per share:
Income from continuing operations$7.25 
The unaudited pro forma information for fiscal year 2021 has been calculated after applying the Company’s accounting policies and the impact of acquisition date fair value adjustments. The fiscal year 2021 unaudited pro forma income from continuing operations was adjusted to exclude approximately $43.2 million of acquisition-related transaction costs and $23.3 million of costs of bridge financing and debt pre-issuance hedges that were recognized in expense during fiscal year 2021. These pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments, such as fair value adjustment to inventory, increased interest expense on debt obtained to finance the transaction, and increased amortization for the fair value of acquired intangible assets.
The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities. The actual results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors.
Other acquisitions in 2021. During fiscal year 2021, the Company also completed the acquisition of seven other businesses for aggregate consideration of $1.2 billion. The acquired businesses include Oxford Immunotec Global PLC, a company based in Abingdon, UK with approximately 275 employees, for total consideration of $590.9 million and Nexcelom Bioscience Holdings, LLC, a company based in Lawrence, Massachusetts with approximately 130 employees, for total consideration of $267.3 million, and five other businesses, which were acquired for total consideration of $318.6 million. The
excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. Identifiable definite-lived intangible assets, such as core technology, trade names, and customer relationships, acquired as part of these acquisitions had a weighted-average amortization period of 12.4 years.
The total purchase price for the acquisitions in fiscal year 2021 has been allocated to the estimated fair value of assets acquired and liabilities assumed as follows:
Final
BioLegendOther
(In thousands)
Fair value of business combinations:
Cash payments$3,336,115 $1,128,584 
Common stock issued2,638,369 — 
Other liability6,857 2,910 
Contingent consideration— 45,031 
Working capital and other adjustments— 183 
Less: cash acquired(292,377)(195,010)
Total$5,688,964 $981,698 
Identifiable assets acquired and liabilities assumed:
Current assets$184,704 $71,840 
Property, plant and equipment147,200 26,507 
Other assets9,330 15,527 
Identifiable intangible assets:
Core technology and clone library782,400 290,089 
Trade names and patents38,000 39,476 
Licenses8,979 — 
Customer relationships and backlog1,714,800 141,670 
Goodwill3,509,931 545,262 
Deferred taxes(668,919)(80,923)
Deferred revenue— (1,197)
Debt assumed— (4,628)
Liabilities assumed(37,461)(61,925)
Total$5,688,964 $981,698 
The Company does not consider the acquisitions completed during fiscal years 2022 and 2021, with the exception of the BioLegend acquisition, to be material to its consolidated results of operations; therefore, the Company is only presenting pro forma financial information of operations for the BioLegend acquisition. The aggregate revenue and results of operations for acquisitions completed during fiscal years 2022 and 2021 for the fiscal year period from their respective acquisition dates were not material.
The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration
liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period.
As of December 31, 2023, the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $98.0 million. As of December 31, 2023, the Company has recorded contingent consideration obligations of $40.0 million, of which $11.0 million was recorded in accrued expenses and other current liabilities, and $29.0 million was recorded in long-term liabilities. The expected maximum earnout period for acquisitions with open contingency periods is 7.9 years from December 31, 2023, and the remaining weighted average expected earnout period at December 31, 2023 was 5.0 years.
If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional contingent consideration which would be recognized as a component of operating expenses from continuing operations.
Total acquisition and divestiture-related costs, included in selling, general and administrative expense in the Company’s consolidated statements of operations, were $69.2 million, $39.8 million and $62.8 million for fiscal years 2023, 2022 and 2021. These amounts included $34.3 million of rebranding expenses in fiscal year 2023 and $20.0 million, $26.5 million and $6.9 million of stock compensation expense related to awards given to BioLegend employees in fiscal years 2023, 2022 and 2021, respectively. Total acquisition and divestiture-related costs, included in interest and other expense, net in the Company’s consolidated statements of operations, were $19.9 million and $18.0 million for fiscal years 2023 and 2021. These amounts included $24.1 million of net foreign exchange loss and $4.2 million interest income related to the sale of the Business in fiscal year 2023, and $5.4 million of net foreign exchange gain and $23.4 million of costs of bridge financing and debt pre-issuance hedges related to the BioLegend acquisition in fiscal year 2021. These acquisition and divestiture-related costs were expensed as incurred.
v3.24.0.1
Nature of Operations and Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies
Nature of Operations:    Revvity, Inc. (the “Company”) is a leading provider of health sciences solutions, technologies, expertise and services that deliver complete workflow from discovery to development, and diagnosis to cure. The Company has two operating segments: Life Sciences and Diagnostics. The Company’s Life Sciences segment focuses on service and innovating for customers spanning the life sciences market. The Company’s Diagnostics segment is targeted towards meeting the needs of clinically-oriented customers, especially within the growing areas of reproductive health, emerging market diagnostics and applied genomics.
Effective as of April 26, 2023, the Company changed its name from “PerkinElmer, Inc.” to “Revvity, Inc.”. Effective as of May 16, 2023, the Company changed the ticker symbol for its common stock to “RVTY” and the ticker symbol for its 1.875% Notes due 2026 to “RVTY 26”.
The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In March 2023, the Company completed the previously announced sale of certain assets and the equity interests of certain entities constituting the Company’s Applied, Food and Enterprise Services businesses (the “Business”). The Business is reported for all periods as discontinued operations in the Company’s consolidated financial statements.
The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a
52/53-week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 31, 2023 (“fiscal year 2023”), January 1, 2023 (“fiscal year 2022”) and January 2, 2022 (“fiscal year 2021”) included 52 weeks. The fiscal year ending December 29, 2024 (“fiscal year 2024”) will include 52 weeks.
Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Revenue Recognition: The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The Company recognizes revenue in an amount that reflects the consideration the Company expects to receive in exchange for the promised products or services when a performance obligation is satisfied by transferring control of those products or services to customers.
Taxes that are collected by the Company from a customer and assessed by a governmental authority, that are both imposed on and concurrent with a specific revenue-producing transaction, are excluded from revenue.
The Company reports shipping and handling revenue in revenue, to the extent it is billed to customers, and the associated costs in cost of product revenue.
Inventories: Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements.
Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not.
The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present
related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense.
The Company is subject to the Global Intangible Low Taxed Income (“GILTI”) tax in the U.S. The Company elected to treat taxes on future GILTI inclusions in U.S. taxable income as a current period expense when incurred.
The Company uses the portfolio approach for releasing income tax effects from accumulated other comprehensive income.
Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements - estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 8 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed.
Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company’s fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds.
Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive income (“AOCI”), a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net.
Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses. Measurement period adjustments are made in the period in which the amounts are determined, and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.
Goodwill and Other Intangible Assets:  The Company’s intangible assets consist of (i) goodwill, which is not being amortized; and (ii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives.
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values.
Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model or the quoted price of the Company’s stock on the grant
date. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock.
 Marketable Securities and Investments:  Investments in debt securities that are classified as available for sale are recorded at fair value with unrealized gains and losses included in AOCI until realized. Investments in debt securities that are classified as held-to-maturity are recorded at amortized cost. Investments in equity securities are recorded at fair values with unrealized holding gains and losses included in earnings. Investments in equity securities without a readily determinable fair values are carried at cost minus impairment, if any. When an observable price change in orderly transactions for the identical or a similar investment of the same issuer has occurred, the Company elects to carry those equity investments at fair value as of the date that the observable transaction occurred.
Cash and Cash Equivalents: The Company considers all highly liquid, unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.
Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.
 Research and Development: Research and development costs are expensed as incurred.
Restructuring and Other Costs: Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. The Company recorded restructuring charges, included in selling, general and administrative expenses in the consolidated statements of operations, of $26.6 million, $13.6 million and $14.4 million primarily associated with workforce reductions during fiscal years 2023, 2022 and 2021, respectively. The Company expects severance payments will be substantially completed during fiscal year 2024.
Comprehensive Income:  Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.
Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting.
For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive income (loss) and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements.
The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold.
Leases: Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized based on the present value of the remaining lease payments over the lease term. When the Company’s lease did not provide an implicit rate, the Company used its incremental borrowing rate in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.
The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component.
The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statements of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred.
As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under Accounting Standards Codification 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with Accounting Standards Codification 842, Leases (“ASC 842”).
Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 will require public entities to disclose on an annual basis a tabular reconciliation using both percentages and amounts, broken out into specific categories with certain reconciling items at or above 5% of the statutory (i.e. expected) tax further broken out by nature and/or jurisdiction. ASU 2023-09 requires all entities to disclose on an annual basis the amount of income taxes paid (net of refunds received), disaggregated between federal (national), state/local and foreign, and amounts paid to an individual jurisdiction when 5% or more of the total income taxes paid. The guidance is required to be applied on a prospective basis; retrospective application is permitted. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. Although the guidance only requires additional disclosures, the Company is in the process of determining the impact of this guidance to its income tax disclosures.
In November 2023, t
v3.24.0.1
Revenue from Contract with Customer
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block] Revenue
For arrangements with multiple performance obligations, the Company accounts for individual products and services separately if they are distinct - i.e., if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated to each performance obligation in an arrangement based on relative stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis.
The Company sells products and services predominantly through its direct sales force, and the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty).
In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year.
Nature of goods and services
The Life Sciences segment principally generates revenue from sales of instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services in the life sciences market. The Diagnostics segment principally generates revenue from sales of instruments, solutions, consumables, reagents, and services in the diagnostics market. The typical length of a contract for service is 12 to 36 months.
The revenue generated from the sale of instruments (inclusive of consumables), reagents, and certain software is recognized at a point in time. The Company recognizes revenue in these arrangements at the point in time when control of the products has been transferred to customers, which is typically at delivery. Certain of the Company's products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. When the Company places the instrument at the customer's site and sells the reagents to a customer, the instrument and reagents are accounted for together as one performance obligation. The Company does not charge a fee for the use of the instrument and retains ownership of the placed instrument. The Company recognizes revenue upon delivery of reagents, which is the point in time where the Company has performed its obligation to provide a screening solution to the customer. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days.
The revenue generated from the sale of licenses for software as a service, cloud services, subscriptions, and laboratory services and training is recognized over time. Term licenses, subscriptions and cloud services, are generally recognized ratably over the contract period. The Company sells its software subscriptions and cloud services with maintenance services and, in some cases, with consulting services. The Company recognizes revenue for the software commencing when the service is made available to the customer. For maintenance and consulting services, revenue is recognized over the period in which the services are provided. Revenue for laboratory services is recognized over the contract period or when the service is billable, based on time and materials.
Product revenue is recognized at a point in time and service revenue is generally recognized over time.
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical market and major good and service lines.
Reportable Segments
For the fiscal year ended
December 31, 2023January 1, 2023January 2, 2022
Life
 Sciences		DiagnosticsTotalLife SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$671,738 $543,875 $1,215,613 $683,170 $979,473 $1,662,643 $444,459 $1,362,213 $1,806,672 
Europe308,567 438,457 747,024 297,468 534,343 831,811 234,334 982,476 1,216,810 
Asia312,035 475,899 787,934 312,271 505,097 817,368 217,076 587,250 804,326 
$1,292,340 $1,458,231 $2,750,571 $1,292,909 $2,018,913 $3,311,822 $895,869 $2,931,939 $3,827,808 
Major goods/service lines
Life Sciences reagents$732,789 $— $732,789 $691,344 $— $691,344 $399,518 $— $399,518 
Life Sciences instruments381,262 — 381,262 405,554 — 405,554 329,584 — 329,584 
Life Sciences software178,289 — 178,289 196,011 — 196,011 166,767 — 166,767 
Reproductive health— 501,302 501,302 — 516,574 516,574 — 514,863 514,863 
Applied genomics— 228,443 228,443 — 393,602 393,602 — 619,357 619,357 
Immunodiagnostics— 728,486 728,486 — 1,108,737 1,108,737 — 1,797,719 1,797,719 
$1,292,340 $1,458,231 $2,750,571 $1,292,909 $2,018,913 $3,311,822 $895,869 $2,931,939 $3,827,808 

Major Customer Concentration
No single customer comprises more than 10% of net revenues during the fiscal year 2023. Revenues from one customer in the Company’s Diagnostics segment represent approximately $330.7 million and $638.6 million of the Company’s total revenue during the fiscal years 2022 and 2021, respectively.
Contract Balances
v3.24.0.1
Discontinued Operations
 12 Months Ended
Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations Discontinued Operations
As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. When the discontinued operations represented a strategic shift that will have a major effect on the Company’s operations and financial statements, the Company has accounted for these businesses as discontinued operations and accordingly, has presented the results of operations and related cash flows as discontinued operations.
On March 13, 2023, the Company completed the previously announced sale of the Business (the “Closing”) to PerkinElmer Topco, L.P. (formerly known as Polaris Purchaser, L.P.) (the “Purchaser”), a Delaware limited partnership owned by funds managed by affiliates of New Mountain Capital L.L.C. (the “Sponsor”), for an aggregate purchase price of up to $2.45 billion. The Company received approximately $2.13 billion in cash proceeds, before transaction costs and subject to post-closing adjustments. The Company is entitled to an additional $75.0 million in proceeds as consideration for the Company’s ceasing the use of the PerkinElmer brand and related trademarks and transferring them to the Purchaser. This consideration is expected to be received in installments through the first half of 2025. The discounted value of the $75.0 million was measured as $65.2 million and was included in the proceeds. In addition, the Company is entitled to additional consideration of up to $150.0 million that is contingent on the exit valuation the Sponsor and its affiliated funds receive on a sale or other capital events related to the Business. The fair value of this element of consideration was determined to be $15.9 million and was included in the proceeds at Closing. The Company also recorded a receivable, included in Other current assets in the consolidated balance sheets, of approximately $160.2 million as of December 31, 2023 for post-closing adjustments that is expected to be received during fiscal year 2024. The final amount of the receivable related to the post-closing adjustments is subject to change.
The Company has measured the gain on sale and related income tax provision, however, additional adjustments may arise that may impact the final measurement of the gain. The elements of the gain calculation that may result in adjustments include
the measurement of the proceeds, including the settlement of the post-closing adjustments, as well as the related tax effects of such adjustments and the filing of tax returns for the period that includes the sale.
In connection and concurrent with the Closing, the Company has also entered into a Transition Services Agreement (“TSA”) with the Purchaser for a period of up to 24 months from the Closing and a Contract Manufacturing Agreement (“CMA”) for two locations which expired in June 2023. The costs and amounts of reimbursements related to the CMA were not significant. The costs and amounts of reimbursements related to the TSA and other commercial transactions between the parties were not significant in fiscal year 2023 and the amounts in future periods are not expected to be significant.
The Business had been reported in the Company’s Discovery & Analytical Solutions segment, which is now referred to as the Life Sciences segment. The sale of the Business represents a strategic shift that will have a major effect on the Company's operations and financial statements. Accordingly, the Business is reported for all periods as discontinued operations in the Company’s consolidated financial statements. The following table summarizes the results of discontinued operations which are presented as income from discontinued operations in the Company’s consolidated statements of operations:
 December 31, 2023January 1, 2023January 2, 2022
 (In thousands)
Revenue$176,324 $1,298,376 $1,239,361 
Cost of revenue125,219 859,330 822,048 
Selling, general and administrative expenses78,613 306,032 268,760 
Research and development expenses10,434 64,605 74,632 
Operating (loss) income(37,942)68,409 73,921 
Other income:
Gain on sale811,472 — — 
Other (expense) income, net(49)5,195 2,383 
Total other income811,423 5,195 2,383 
Income from discontinued operations before income taxes773,481 73,604 76,304 
Provision for income tax259,890 17,101 22,583 
Income from discontinued operations$513,591 $56,503 $53,721 
The table below provides a reconciliation of the carrying amounts of the major classes of assets and liabilities of the discontinued operations to the amounts presented separately in the consolidated balance sheet at January 1, 2023.
January 1, 2023
 (In thousands)
Cash and cash equivalents$14,999 
Accounts receivable343,064 
Inventories210,367 
Other current assets32,063 
Total current assets600,493 
Property, plant and equipment, net60,983 
Operating lease right-of-use assets41,487 
Intangible assets, net202,850 
Goodwill772,812 
Other assets, net15,079 
    Total long-term assets
1,093,211 
Total assets of discontinued operations
$1,693,704 
Accounts payable29,912 
Accrued expenses and other current liabilities161,260 
    Total current liabilities191,172 
Deferred taxes and long-term liabilities46,046 
Operating lease liabilities35,647 
    Total long-term liabilities81,693 
Total liabilities of discontinued operations$272,865 
The following operating and investing items from discontinued operations were as follows for the fiscal years ended:
December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Depreciation
$— $8,011 $12,897 
Amortization
— 16,984 33,664 
Capital expenditures1,292 10,670 13,868 
v3.24.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The components of income from continuing operations before income taxes were as follows for the fiscal years ended:
 
December 31,
2023		January 1,
2023		January 2,
2022
(In thousands)
U.S.$51,314 $326,438 $547,705 
Non-U.S.131,662 325,399 655,877 
Total$182,976 $651,837 $1,203,582 
The components of the provision for income taxes on continuing operations were as follows:
 
Current
Expense		Deferred 
Expense
(Benefit)		Total
(In thousands)
Fiscal year ended December 31, 2023
Federal$39,800 $(60,845)$(21,045)
State9,183 (19,619)(10,436)
Non-U.S.78,154 (43,200)34,954 
Total$127,137 $(123,664)$3,473 
Fiscal year ended January 1, 2023
Federal$115,436 $(45,246)$70,190 
State27,757 (16,139)11,618 
Non-U.S.101,891 (44,538)57,353 
Total$245,084 $(105,923)$139,161 
Fiscal year ended January 2, 2022
Federal$154,905 $(37,858)$117,047 
State53,961 3,602 57,563 
Non-U.S.160,608 (21,072)139,536 
Total$369,474 $(55,328)$314,146 
The total provision for income taxes included in the consolidated financial statements is as follows for the fiscal years ended: 
December 31,
2023		January 1,
2023		January 2,
2022
(In thousands)
Continuing operations$3,473 $139,161 $314,146 
Discontinued operations259,890 17,101 22,583 
Total$263,363 $156,262 $336,729 
 A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended:
 
December 31,
2023		January 1,
2023		January 2,
2022
(In thousands)
Tax at statutory rate$38,346 $136,886 $252,752 
Non-U.S. rate differential, net(18,479)(5,221)(33,847)
U.S. taxation of multinational operations(4,594)22,102 7,964 
State income taxes, net(265)7,820 36,832 
Impact of rate changes(12,795)— 14,031 
Prior year tax matters3,971 (10,160)1,850 
Effect of stock compensation2,225 845 (2,187)
General business tax credits(4,718)(7,132)(2,715)
Transfer pricing matters(6,725)— — 
Change in valuation allowance6,772 4,964 (179)
Effect of foreign repatriations(4,737)(4,940)37,147 
Other, net4,472 (6,003)2,498 
Total$3,473 $139,161 $314,146 
The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position.
The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended:
December 31,
2023		January 1,
2023		January 2,
2022
(In thousands)
Unrecognized tax benefits, beginning of year$57,948 $61,658 $38,773 
Gross increases—tax positions in prior periods64,697 1,489 2,877 
Gross decreases—tax positions in prior periods— (2,519)— 
Gross increases—current-period tax positions14,969 7,187 149 
Gross increases related to acquisitions— — 22,697 
Settlements— — (2,252)
Lapse of statute of limitations(10,830)(8,625)(563)
Foreign currency translation adjustments2,272 (1,242)(23)
Unrecognized tax benefits, end of year$129,056 $57,948 $61,658 
The Company classifies interest and penalties as a component of income tax expense. At December 31, 2023 and January 1, 2023, the Company had accrued interest and penalties of $6.3 million and $7.2 million, respectively. During fiscal years 2023, 2022 and 2021, the Company recognized a net (benefit) expense of $(1.1) million, $(0.5) million and $1.8 million, respectively, for interest and penalties in its total tax provision. At December 31, 2023, substantially all of the unrecognized tax benefits, if recognized, would affect the effective tax rate.
The Company believes that it is reasonably possible that approximately $71.6 million of its uncertain tax positions at December 31, 2023, including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2010 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as China, Finland, Germany, Luxembourg, The Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction.
The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities were as follows: 
December 31,
2023		January 1,
2023
(In thousands)
Deferred tax assets:
Inventory$12,934 $17,920 
Reserves and accruals63,711 70,912 
Accrued compensation18,339 23,868 
Net operating loss and credit carryforwards133,919 117,953 
Accrued pension11,089 11,653 
Restructuring reserve1,588 1,640 
Deferred revenue17,539 22,644 
Capitalized research and development expenses47,188 44,922 
Operating lease liabilities29,319 43,547 
Unrealized foreign exchange loss
12,502 11,158 
All other, net1,610 841 
Total deferred tax assets349,738 367,058 
Deferred tax liabilities:
Postretirement health benefits(4,452)(4,379)
Depreciation and amortization(784,925)(916,581)
Operating lease right-of-use assets(26,301)(39,281)
Prepaid expenses(349)(3,515)
Deferred tax liability on foreign earnings(17,587)(15,782)
Total deferred tax liabilities(833,614)(979,538)
Valuation allowance(84,626)(96,681)
Net deferred tax liabilities$(568,502)$(709,161)

The components of net deferred tax liabilities were recognized in the consolidated balance sheets as follows:
December 31,
2023		January 1,
2023
(In thousands)
Other assets, net$8,158 $18,527 
Deferred taxes and other long-term liabilities(576,660)(727,688)
Total$(568,502)$(709,161)

At December 31, 2023, the Company had U.S. federal net operating loss carryforwards of $109.8 million, state net operating loss carryforwards of $8.9 million, foreign net operating loss carryforwards of $439.8 million, state tax credit carryforwards of $13.8 million and general business tax credit carryforwards of $0.1 million. Certain net operating loss carryforwards and state credit carryforwards do not expire, while other losses begin to expire in 2024.
Valuation allowances take into consideration limitations imposed upon the use of the tax attributes and reduce the value of such items to the likely net realizable amount. The Company regularly evaluates positive and negative evidence available to determine if valuation allowances are required or if existing valuation allowances are no longer required. Valuation allowances have been provided on state net operating loss and state tax credit carryforwards and on certain foreign tax attributes that the Company has determined are not more likely than not to be realized.
The Company is no longer permanently reinvested in the undistributed earnings of its international subsidiaries that have been previously taxed at the U.S. federal level and/or would be subject to a dividend received deduction if repatriated. The Company recorded the applicable taxes that will be due when such earnings are repatriated. For the remaining other undistributed foreign earnings and outside basis differences, the Company continues to be indefinitely reinvested and have not
provided any taxes for these amounts, and it is not practicable to estimate the amount of deferred tax liability that would be incurred.
v3.24.0.1
Earnings Per Share
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended:

December 31,
2023		January 1,
2023		January 2,
2022
(In thousands)
Number of common shares—basic124,704 126,155 116,165 
Effect of dilutive securities:
Stock options108 249 391 
Restricted stock awards— 22 118 
Number of common shares—diluted124,812 126,426 116,674 
Number of potentially dilutive securities excluded from calculation due to antidilutive impact1,089 611 487 
Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive securities also include restricted stock awards with average unrecognized compensation cost in excess of the average fair market value of the common stock for the related period. Antidilutive options and restricted stock awards were excluded from the calculation of diluted net income per share and could become dilutive in the future.
v3.24.0.1
Accounts Receivable, Net
 12 Months Ended
Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]  
Accounts Receivable, Net Accounts Receivable, Net
Accounts receivable, net consisted of the following:
 
December 31,
2023		January 1,
2023
(In thousands)
Accounts receivable, net$632,811 $612,780 
Long-term accounts receivable, net, included in Other assets, net29,593 34,040 
Total accounts receivable, net$662,404 $646,820 
Reserves for credit losses consisted of the following:
Balance at Beginning of YearProvisionsCharges/
Write-offs
Other(1)
Balance at End
of Year
  (In thousands)
Year ended January 2, 2022$33,497 $6,854 $(2,198)$101 $38,254 
Year ended January 1, 202338,254 9,857 (9,672)(896)37,543 
Year ended December 31, 202337,543 9,067 (3,559)329 43,380 
(1) Other amounts primarily relate to the impact of acquisitions, discontinued operations and foreign exchange movements.
v3.24.0.1
Inventories, Net
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Inventories, Net Inventories, Net
Inventories, net consisted of the following:
 
December 31,
2023		January 1,
2023
(In thousands)
Raw materials$197,268 $190,640 
Work in progress69,176 68,206 
Finished goods161,618 146,616 
Total inventories, net$428,062 $405,462 
v3.24.0.1
Property, Plant and Equipment, Net
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment, Net [Abstract]  
Property, Plant and Equipment, Net Property, Plant and Equipment, Net
Property, plant and equipment consisted of the following:
December 31,
2023		January 1,
2023
(In thousands)
At cost:
Land$29,635 $28,340 
Building and leasehold improvements358,380 346,164 
Machinery and equipment595,124 482,639 
Total property, plant and equipment983,139 857,143 
Accumulated depreciation(473,485)(374,193)
Total property, plant and equipment, net$509,654 $482,950 
Depreciation expense on property, plant and equipment for the fiscal years ended December 31, 2023, January 1, 2023 and January 2, 2022 was $66.7 million, $56.4 million and $54.9 million, respectively.
v3.24.0.1
Marketable Securities and Investments
 12 Months Ended
Dec. 31, 2023
Marketable Securities [Abstract]  
Marketable Securities and Investments Marketable Securities and Investments
 Investments consisted of the following:
 
December 31,
2023		January 1,
2023
(In thousands)
Marketable securities - held to maturity (current)$689,916 $— 
Marketable securities - available for sale13,913 11,083 
Equity investments57,206 54,503 
Notes receivables and other investments12,280 42,500 
$773,315 $108,086 
Marketable securities - held to maturity. The Company’s investments in U.S. treasury securities are classified as held-to-maturity and measured at amortized cost. All the outstanding investments in U.S. treasury securities had a contractual maturity of less than one year as of December 31, 2023 and have been classified as current in the consolidated balance sheet to match the maturities of the long-term debt expected to be retired concurrently with the maturity of the marketable securities.
Marketable securities - available for sale. Marketable securities, which are included in Other assets, net, are accounted for as available for sale and include equity and fixed-income securities. The net unrealized holding gain and loss on marketable securities, net of deferred income taxes, reported as a component of other comprehensive income (loss) in the consolidated statements of stockholders’ equity, was not material. The proceeds from the sales of securities and the related gains and losses are not material for any period presented.
Equity Investments. The Company has equity interests in privately-held entities over which the Company neither has significant influence nor control. Equity investments, which are included in Other assets, net, as of December 31, 2023 and January 1, 2023 consisted of the following:
December 31,
2023		January 1,
2023
(In thousands)
Equity investments, carried at cost minus impairment, if any$47,260 $50,654 
Equity investments, carried at fair value9,946 3,849 
$57,206 $54,503 
The amount of upward adjustments during the periods presented were not material. The cumulative amount of upward adjustments as of December 31, 2023 and January 1, 2023 was $31.3 million and $30.7 million, respectively. The cumulative amount of impairments and downward adjustments as of each of December 31, 2023 and January 1, 2023 was $5.0 million.
Notes receivables and other investments. Notes receivables and other investments, which are included in Other assets, net, are carried at cost less allowance for credit losses. The amortized cost of these investments are not materially different than the fair value. Notes receivables and other investments with a notional amount of $19.8 million are due within one to five years. Notes receivables and other investments with a notional amount of $25.0 million and a carrying value of $12.3 million are convertible into equity securities or are due and payable upon an event of default (as defined in the applicable agreement). The credit losses, included in Interest and other expense, net, in the consolidated statements of operations, during fiscal year 2023 were $34.5 million.
v3.24.0.1
Goodwill and Intangible Assets, Net
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
The Company tests goodwill at least annually for possible impairment. The Company completes the annual testing of impairment for goodwill on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill.
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. The Company performed its annual impairment testing for its
reporting units as of January 2, 2023, its annual impairment testing date for fiscal year 2023. The Company concluded based on the first step of the process that there was no goodwill impairment.
The changes in the carrying amount of goodwill for fiscal years 2023 and 2022 are as follows:
Life SciencesDiagnosticsConsolidated
(In thousands)
Balance at January 2, 2022$4,656,769 $1,970,350 $6,627,119 
Foreign currency translation(98,268)(41,617)(139,885)
Acquisitions, earnouts and measurement period adjustments(6,926)1,460 (5,466)
Balance at January 1, 20234,551,575 1,930,193 6,481,768 
Foreign currency translation36,363 15,419 51,782 
Balance at December 31, 2023$4,587,938 $1,945,612 $6,533,550 

Identifiable intangible asset balances at December 31, 2023 and January 1, 2023 were as follows:
December 31,
2023		January 1,
2023
(In thousands)
Patents$27,811 $28,020 
Less: Accumulated amortization(26,072)(26,055)
Net patents1,739 1,965 
Trade names and trademarks145,542 149,453 
Less: Accumulated amortization(73,781)(63,590)
Net trade names and trademarks71,761 85,863 
Licenses27,018 62,614 
Less: Accumulated amortization(16,551)(54,254)
Net licenses10,467 8,360 
Core technology1,582,458 1,556,740 
Less: Accumulated amortization(607,814)(449,689)
Net core technology974,644 1,107,051 
Customer relationships2,842,531 2,943,761 
Less: Accumulated amortization(878,821)(775,104)
Net customer relationships1,963,710 2,168,657 
In-process research and development— 5,278 
Net amortizable intangible assets$3,022,321 $3,377,174 
Total amortization expense related to amortizable intangible assets was $365.1 million in fiscal year 2023, $370.6 million in fiscal year 2022 and $256.6 million in fiscal year 2021. Estimated amortization expense related to amortizable intangible assets for each of the next five years is $362.6 million in fiscal year 2024, $335.0 million in fiscal year 2025, $328.8 million in fiscal year 2026, $301.6 million in fiscal year 2027, and $275.9 million in fiscal year 2028.
v3.24.0.1
Debt
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Debt Debt
 The Company’s debt consisted of the following:
December 31, 2023
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(1,966)$(1,966)
€500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”)553,450 (1,438)(1,279)550,733 
1.900% Senior Unsecured Notes due in 2028 (“2028 Notes”)
500,000 (250)(3,024)496,726 
3.3% Senior Unsecured Notes due in 2029 (“2029 Notes”)850,000 (1,727)(4,781)843,492 
2.55% Senior Unsecured Notes due in March 2031 (“March 2031 Notes”)400,000 (101)(2,638)397,261 
2.250% Senior Unsecured Notes due in September 2031 (“September 2031 Notes”)
500,000 (1,210)(3,568)495,222 
3.625% Senior Unsecured Notes due in 2051 (“2051 Notes”)400,000 (4)(4,158)395,838 
Other Debt Facilities, non-current464 — — 464 
Total Long-Term Debt3,203,914 (4,730)(21,414)3,177,770 
Current Portion of Long-term Debt:
0.850% Senior Unsecured Notes due in 2024 (“2024 Notes”)
711,479 (118)(1,301)710,060 
Other Debt Facilities, current11,812 — — 11,812 
Total Current Portion of Long-Term Debt723,291 (118)(1,301)721,872 
Total Debt$3,927,205 $(4,848)$(22,715)$3,899,642 
January 1, 2023
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(2,641)$(2,641)
2024 Notes771,659 (283)(3,136)768,240 
2026 Notes533,950 (1,902)(1,779)530,269 
2028 Notes500,000 (301)(3,631)496,068 
2029 Notes850,000 (2,000)(5,537)842,463 
March 2031 Notes400,000 (114)(2,978)396,908 
September 2031 Notes500,000 (1,353)(3,991)494,656 
2051 Notes400,000 (4)(4,260)395,736 
Other Debt Facilities, non-current1,648 — — 1,648 
Total Long-Term Debt3,957,257 (5,957)(27,953)3,923,347 
Current Portion of Long-term Debt:
0.550% Senior Unsecured Notes due in September 2023 (“2023 Notes”)467,138 (63)(867)466,208 
Other Debt Facilities, current4,721 — — 4,721 
Total Current Portion of Long-Term Debt471,859 (63)(867)470,929 
Total Debt$4,429,116 $(6,020)$(28,820)$4,394,276 

Senior Unsecured Revolving Credit Facility. On August 24, 2021, the Company entered into a new senior unsecured revolving credit facility with a five-year term and a borrowing capacity of $1.5 billion available through August 24, 2026. As of
December 31, 2023, undrawn letters of credit in the aggregate amount of $7.1 million were treated as issued and outstanding when calculating the borrowing availability under the facility. As of December 31, 2023, the Company had $1.49 billion available for additional borrowing under the facility. Borrowings will bear interest, payable quarterly or, if earlier, at the end of any interest period, at the Company’s option at either (a) the base rate (as defined in the credit agreement), or (b) the eurocurrency rate (a publicly published rate), in each case plus a percentage spread based on the credit rating of the Company’s debt. The base rate is the highest of (a) the Federal Funds Rate (as defined in the credit agreement) plus 0.50%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate”, and (c) the Eurocurrency Rate plus 1.00%. The credit agreement for the new facility contains customary affirmative, negative and financial covenants and events of default. The financial covenants include a debt-to-capital ratio that remains applicable for so long as the Company’s debt is rated as investment grade. In the event that the Company’s debt is not rated as investment grade, a debt-to-capital ratio covenant is replaced with leverage ratio and interest coverage ratio covenants.
During the fiscal year 2023, the Company paid in full $467.1 million of outstanding 2023 Notes. During fiscal year 2023, the Company repurchased $60.2 million in aggregate principal amount of the 2024 Notes in open market transactions. At December 31, 2023, the Company had outstanding U.S. treasury securities with a carrying amount of $689.9 million whose proceeds upon maturity are intended to be utilized to repay the outstanding 2024 Notes due in September 2024 (see Note 11).
The following table summarizes the maturities of the Company’s indebtedness as of December 31, 2023: 
(In thousands)
2024$723,291 
2025206 
2026553,570 
202792 
2028500,046 
2029 and thereafter2,150,000 
Total debt payments3,927,205 
Less unamortized discount and debt issuance costs(27,563)
Total$3,899,642 
v3.24.0.1
Accrued Expenses and Other Current Liabilities
 12 Months Ended
Dec. 31, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Accrued Expenses and Other Current Liabilities Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following:
 
December 31,
2023		January 1,
2023
(In thousands)
Payroll and incentives$50,526 $52,331 
Employee benefits43,279 51,983 
Deferred revenue135,555 135,531 
Federal, non-U.S. and state income taxes88,159 45,625 
Operating lease liabilities
32,906 31,217 
Other accrued operating expenses174,045 211,176 
Total accrued expenses and other current liabilities$524,470 $527,863 
v3.24.0.1
Employee Benefit Plans
 12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
Employee Benefit Plans Employee Benefit Plans
 Savings Plan:    The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Savings plan expense was $15.0 million in fiscal year 2023, $20.0 million in fiscal year 2022, and $16.5 million in fiscal year 2021.
Pension Plans:    The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan is closed to new hires and plan benefits have been frozen. The plans provide benefits that are based on an employee’s years of service and compensation near retirement.
 Net periodic pension cost for U.S. and non-U.S. plans included the following components for fiscal years ended:
December 31,
2023		January 1,
2023		January 2,
2022
(In thousands)
Service and administrative costs$5,736 $6,331 $5,174 
Interest cost19,585 10,751 9,440 
Expected return on plan assets(14,600)(22,056)(24,417)
Actuarial losses (gains)9,341 (23,706)(19,514)
Net periodic pension cost (credit)$20,062 $(28,680)$(29,317)
The Company recognizes actuarial gains and losses, unless an interim remeasurement is required, in the fourth quarter of the year in which the gains and losses occur. Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company’s control, including changes in interest rates, the performance of the financial markets and mortality assumptions. Actuarial gains and losses, including other components of periodic pension cost, are recognized in the line item “Interest and other expense, net” in the consolidated statements of operations.
The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 31, 2023 and January 1, 2023.
 December 31, 2023January 1, 2023
Non-U.S.U.S.Non-U.S.U.S.
(In thousands)
Actuarial present value of benefit obligations:
Accumulated benefit obligations$227,174 $208,505 $207,503 $231,492 
Change in benefit obligations:
Projected benefit obligations at beginning of year$207,955 $231,492 $339,390 $299,826 
Service and administrative costs4,011 1,725 4,956 1,375 
Interest cost8,843 10,742 3,671 7,080 
Benefits paid and plan expenses(15,061)(39,895)(14,978)(19,870)
Benefit obligation classified in discontinued operations— — (8,261)— 
Actuarial losses (gains)12,871 4,441 (88,724)(56,919)
Effect of exchange rate changes8,960 — (28,099)— 
Projected benefit obligations at end of year$227,579 $208,505 $207,955 $231,492 
Change in plan assets:
Fair value of plan assets at beginning of year$106,741 $216,748 $181,189 $290,116 
Actual return on plan assets7,094 15,478 (46,383)(53,498)
Benefits paid and plan expenses(15,061)(39,895)(14,978)(19,870)
Employer’s contributions7,606 10,000 6,572 — 
Effect of exchange rate changes5,925 — (19,659)— 
Fair value of plan assets at end of year$112,305 $202,331 $106,741 $216,748 
Net liabilities recognized in the consolidated balance sheets$(115,274)$(6,174)$(101,214)$(14,744)
Net amounts recognized in the consolidated balance sheets consist of:
Other assets$19,540 $— $19,521 $— 
Current liabilities(6,899)— (6,568)— 
Long-term liabilities(127,915)(6,174)(114,167)(14,744)
Net liabilities recognized in the consolidated balance sheets$(115,274)$(6,174)$(101,214)$(14,744)
Actuarial assumptions as of the year-end measurement date:
Discount rate3.69 %4.54 %4.12 %4.84 %
Rate of compensation increase3.19 %None3.16 %None
Actuarial assumptions used to determine net periodic pension cost during the year were as follows:
December 31, 2023January 1, 2023January 2, 2022
Non-U.S.U.S.Non-U.S.U.S.Non-U.S.U.S.
Discount rate4.12 %4.84 %1.41 %2.44 %0.92 %2.21 %
Rate of compensation increase3.16 %None2.78 %None2.78 %None
Expected rate of return on assets3.92 %4.80 %1.11 %7.25 %2.10 %7.25 %
 
The Company’s expected rate of return on assets assumptions are derived from management’s estimates, as well as other information compiled by management, including studies that utilize customary procedures and techniques. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study gives appropriate consideration to recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate.
The Company’s discount rate assumptions are derived from a range of factors, including a yield curve for certain plans, composed of the rates of return on high-quality fixed-income corporate bonds available at the measurement date and the related expected duration for the obligations, and a bond matching approach for certain plans.
The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets:
December 31,
2023		January 1,
2023
(In thousands)
Pension Plans with Projected Benefit Obligations in Excess of Plan Assets
Projected benefit obligations$134,814 $120,736 
Fair value of plan assets— — 
Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets
Accumulated benefit obligations$134,409 $120,283 
Fair value of plan assets— — 
 Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 31, 2023 and January 1, 2023, and target asset allocations for fiscal year 2024 are as follows:
 Target AllocationPercentage of Plan Assets at
December 29, 2024December 31, 2023January 1, 2023
Asset CategoryNon-U.S.U.S.Non-U.S.U.S.Non-U.S.U.S.
Equity securities0-5%0-10%— %6 %— %44 %
Debt securities0-5%90-100%— %94 %— %56 %
Other95-100%0-10%100%— %100 %— %
Total100 %100 %100 %100 %100 %100 %
The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans which are designed to maximize the total rate of return (income and appreciation) after inflation within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments.
The target allocations for plan assets are listed in the above table. Equity securities primarily include investments in mutual funds with holdings in large-cap and mid-cap companies located in the United States and abroad. Debt securities include corporate bonds of companies from diversified industries, high-yield bonds, and U.S. government securities. Other types of investments include investments in non-U.S. government index linked bonds, multi-strategy hedge funds, venture capital funds and foreign liability driven investments that follow several different strategies.
The fair value of the Company’s pension plan assets as of December 31, 2023 and January 1, 2023 by asset category, classified in the three levels of inputs described in Note 20 to the consolidated financial statements are as follows:
 
 Fair Value Measurements at December 31, 2023 Using:
Total Carrying
Value at
December 31, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash and cash equivalents$14,223 $14,223 $— $— 
Equity securities:
U.S. large-cap7,011 7,011 — — 
International large-cap value2,350 2,350 — — 
Emerging markets growth1,068 1,068 — — 
Fixed income securities:
Corporate and U.S. debt instruments189,318 65,228 124,090 — 
Other types of investments:
Foreign liability driven instrument100,666 — — 100,666 
Total assets measured at fair value$314,636 $89,880 $124,090 $100,666 
 Fair Value Measurements at January 1, 2023 Using:
Total Carrying
Value at
January 1, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash$14,483 $14,483 $— $— 
Equity Securities:
U.S. large-cap61,680 61,680 — — 
International large-cap value20,148 20,148 — — 
Emerging markets growth9,902 9,902 — — 
Fixed income securities:
Corporate and U.S. debt instruments105,126 36,346 68,780 — 
Corporate bonds17,088 — 17,088 — 
Other types of investments:
Foreign liability driven instrument95,062 — — 95,062 
Total assets measured at fair value$323,489 $142,559 $85,868 $95,062 

Valuation Techniques:    Valuation techniques utilized need to maximize the use of observable inputs and minimize the use of unobservable inputs. There have been no changes in the methodologies utilized at December 31, 2023 compared to January 1, 2023. The following is a description of the valuation techniques utilized to measure the fair value of the assets shown in the table above.

Equity Securities: Mutual funds held by the Master Trust are open‑ended mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Master Trust are deemed to be actively traded. These are categorized as Level 1 assets.

Fixed Income Securities: Fixed income U.S. government bonds are valued at quoted market prices and are categorized as Level 1 assets.
Fixed income corporate bond exchange traded funds or individual fixed income corporate bonds are categorized as Level 2 assets except where sufficient quoted prices exist in active markets, in which case such securities are categorized as Level 1 assets. These securities are valued using third-party pricing services. These services may use, for example, model-based pricing methods that utilize observable market data as inputs. Broker dealer bids or quotes of securities with similar characteristics may also be used.
Other Types of Investments:   In September 2021, the Company’s UK pension scheme executed a buy-in contract with Phoenix Life LTD (“Phoenix”), under which the Company made an upfront payment to Phoenix in exchange for Phoenix agreeing to make the benefit payments under the Company’s UK pension scheme due to specified participants and their beneficiaries, thus transferring most of the investment and longevity risk associated with the covered participants and beneficiaries from the Company to Phoenix. This buy-in contract can be considered a liability-driven investment (“LDI”) solution that hedges not only the investment risk but also the longevity risk under the Company’s UK pension scheme. Like other LDI solutions, it does not eliminate ongoing administrative costs. These are categorized as Level 3 assets.
The Company’s policy is to recognize significant transfers between levels at the actual date of the event.
A reconciliation of the beginning and ending Level 3 foreign liability driven investments is as follows:
 
(In thousands)
Balance at January 2, 2022$165,680 
Pension benefits paid(6,639)
Foreign exchange losses(18,411)
Return on plan assets(45,568)
Balance at January 1, 202395,062 
Pension benefits paid(6,051)
Foreign exchange gains5,957 
Return on plan assets5,698 
Balance at December 31, 2023$100,666 
 
With respect to plans outside of the United States, the Company expects to contribute $6.9 million in the aggregate during fiscal year 2024. During fiscal year 2023, the Company contributed $10.0 million to its defined benefit pension plan in the United States for the plan year 2022.
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
 
Non-U.S.U.S.
(In thousands)
2024$12,331 $18,882 
202512,598 18,583 
202612,720 18,240 
202712,673 17,864 
202812,914 17,408 
2029-203364,702 77,782 
 
The Company also sponsors a supplemental executive retirement plan to provide senior management with benefits in excess of normal pension benefits. Effective July 31, 2000, this plan was closed to new entrants. At December 31, 2023 and January 1, 2023, the projected benefit obligations were $18.6 million and $18.9 million, respectively. Assets with a fair value of $0.6 million and $0.9 million, segregated in a trust (which is included in marketable securities in the Other assets, net, on the consolidated balance sheets), were available to meet this obligation as of December 31, 2023 and January 1, 2023, respectively. Pension expenses and income for this plan netted to expense of $1.5 million in fiscal year 2023, income of $3.2 million in fiscal year 2022 and expense of $0.2 million in fiscal year 2021.
 
Postretirement Medical Plans:  The Company provides healthcare benefits for eligible retired U.S. employees under a comprehensive major medical plan or under health maintenance organizations where available. Eligible U.S. employees qualify for retiree health benefits if they retire directly from the Company and have at least ten years of service. Generally, the major medical plan pays stated percentages of covered expenses after a deductible is met and takes into consideration payments by other group coverage and by Medicare. The plan requires retiree contributions under most circumstances and has provisions for cost-sharing charges. Effective January 1, 2000, this plan was closed to new hires. For employees retiring after 1991, the Company has capped its medical premium contribution based on employees’ years of service. The Company funds the amount allowable under a 401(h) provision in the Company’s defined benefit pension plan. Assets of the plan are primarily equity and debt securities and are available only to pay retiree health benefits. The costs of these plans are not material and the net assets in the plans totaled $18.5 million and $17.1 million at December 31, 2023 and January 1, 2023, respectively.
v3.24.0.1
Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $14.1 million and $12.2 million as of December 31, 2023 and January 1, 2023, respectively, in accrued expenses and other current liabilities, which represents its management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. The Company’s environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded.
The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities, including product liability claims. Legal defense costs are recognized as incurred, and insurance recoveries are recognized when collection is probable. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at the reporting date, the total cost of resolving these contingencies at December 31, 2023 should not have a material adverse effect on the Company’s consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.
v3.24.0.1
Stock Plans
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock Plans Stock Plans
Stock-Based Compensation:
 
The Company’s 2019 Incentive Plan (the “2019 Plan”) authorizes the issuance of stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and cash awards as part of the Company’s compensation programs. The 2019 Plan replaced the Company’s 2009 Incentive Plan (the “2009 Plan”). Upon shareholder approval of the 2019 Plan, 6.25 million shares of the Company’s common stock, as well as shares of the Company’s common stock previously granted under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price subject to a contractual repurchase right, became available for grant under the 2019 Plan. Awards granted under the 2009 Plan prior to its expiration remain outstanding. As part of the Company’s compensation programs, the Company also offers shares of its common stock under its Employee Stock Purchase Plan.
 
The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units, performance units and stock grants, included in the Company’s consolidated statements of operations:
 December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Cost of product and service revenue$4,224 $7,459 $3,193 
Research and development expenses5,276 6,799 2,393 
Selling, general and administrative expenses31,910 37,260 24,089 
Total stock-based compensation expense$41,410 $51,518 $29,675 
The total income tax benefit recognized in the consolidated statements of operations for stock-based compensation was $10.6 million in fiscal year 2023, $12.8 million in fiscal year 2022 and $12.2 million in fiscal year 2021. Stock-based compensation costs capitalized as part of inventory were immaterial in all periods presented.
Stock Options:    The Company has granted options to purchase common shares at prices equal to the market price of the common shares on the date the option is granted. Conditions of vesting are determined at the time of grant. Options are generally exercisable in equal annual installments over a period of three years, and will generally expire seven years after the date of grant. Options replaced in association with business combination transactions are generally issued with the same terms of the respective plans under which they were originally issued.
 
The fair value of each option grant is estimated using the Black-Scholes option pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical and implied volatility of the Company’s stock. The average expected life was based on the contractual term of the option and historic exercise experience. The risk-free interest rate is based on United States Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended:
 
December 31,
2023		January 1,
2023		January 2,
2022
Risk-free interest rate4.1 %2.3 %0.9 %
Expected dividend yield0.2 %0.2 %0.2 %
Expected lives5 years5 years5 years
Expected stock volatility32.7 %28.5 %27.3 %

The following table summarizes stock option activity for the fiscal year ended December 31, 2023:
 
 Number
of
Shares		Weighted-
Average Exercise
Price
 (Shares in thousands)
Outstanding at beginning of year1,048 $132.32 
Granted168 128.35 
Exercised(58)76.12 
Canceled(49)154.37 
Forfeited(36)146.13 
Outstanding at end of year1,073 $133.28 
Exercisable at end of year693 $125.06 
 
The aggregate intrinsic value for stock options outstanding at December 31, 2023 was $9.4 million with a weighted-average remaining contractual term of 4.1 years. The aggregate intrinsic value for stock options exercisable at December 31, 2023 was $9.3 million with a weighted-average remaining contractual term of 3.4 years. At December 31, 2023, there were 1.1 million stock options that were vested and expected to vest in the future, with an aggregate intrinsic value of $9.4 million and a weighted-average remaining contractual term of 4.1 years.
 
The weighted-average grant-date fair value of options granted during fiscal years 2023, 2022 and 2021 was $45.18, $48.09, and $40.00 per share, respectively. The total intrinsic value of options exercised during fiscal years 2023, 2022 and 2021 was $2.4 million, $13.9 million, and $32.4 million, respectively. Cash received from option exercises for fiscal years 2023, 2022 and 2021 was $4.3 million, $14.1 million, and $25.1 million, respectively. The total compensation expense recognized related to the Company’s outstanding options was $9.1 million in fiscal year 2023, $9.5 million in fiscal year 2022 and $5.6 million in fiscal year 2021.
There was $11.2 million of total unrecognized compensation cost related to nonvested stock options granted as of December 31, 2023. This cost is expected to be recognized over a weighted-average period of 1.6 years.
Restricted Stock Awards:    The Company has awarded shares of restricted stock and restricted stock units to certain employees and non-employee directors at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued employment. The fair value of the award at the time of the grant is expensed on a straight-line basis primarily in selling, general
and administrative expenses over the vesting period, which is generally 3 years. Recipients of the restricted stock have the right to vote such shares and receive dividends.
 
The following table summarizes restricted stock award activity for the fiscal year ended December 31, 2023:
 
Number
of
Shares		Weighted-
Average
Grant-
Date Fair
Value
 (Shares in thousands)
Nonvested at beginning of year453 $152.79 
Granted139 128.79 
Vested(221)142.69 
Forfeited(30)147.80 
Nonvested at end of year341 $149.98 
 
The fair value of restricted stock awards vested during fiscal years 2023, 2022 and 2021 was $31.5 million, $32.8 million, and $11.6 million, respectively. The total compensation expense recognized related to the restricted stock awards was $28.3 million in fiscal year 2023, $34.2 million in fiscal year 2022 and $16.3 million in fiscal year 2021.
 
As of December 31, 2023, there was $27.1 million of total unrecognized compensation cost, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.5 years.
Employee Stock Purchase Plan:
In April 1999, the Company’s shareholders approved the 1998 Employee Stock Purchase Plan. In April 2005, the Compensation and Benefits Committee of the Company's Board of Directors (the “Board”) voted to amend the Employee Stock Purchase Plan, effective July 1, 2005, whereby participating employees have the right to purchase common stock at a price equal to 95% of the closing price on the last day of each six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee’s voluntary contribution, which may not exceed 10% of the employee’s base compensation. During fiscal year 2023, the Company issued 28,899 shares of common stock under the Company’s Employee Stock Purchase Plan at a weighted-average price of $108.37 per share. During fiscal year 2022, the Company issued 30,818 shares under this plan at a weighted-average price of $134.05 per share. During fiscal year 2021, the Company issued 21,578 shares under this plan at a weighted-average price of $168.11 per share. At December 31, 2023 there remains available for sale to employees an aggregate of 0.7 million shares of the Company’s common stock out of the 5.0 million shares authorized by shareholders for issuance under this plan.
v3.24.0.1
Stockholders' Equity
 12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ Equity
Comprehensive Income:
The components of accumulated other comprehensive income (loss) consisted of the following:
 
Foreign
Currency
Translation
Adjustment,
net of tax		Unrecognized
Prior Service
Costs, net of
tax		Unrealized
(Losses)
Gains on
Securities,
net of tax		Accumulated
Other
Comprehensive
Income (Loss)
 (In thousands)
Balance, January 3, 2021$(30,937)$(747)$(277)$(31,961)
Current year change(130,873)(95)237 (130,731)
Balance, January 2, 2022(161,810)(842)(40)(162,692)
Current year change(284,854)44 5 (284,805)
Balance, January 1, 2023(446,664)(798)(35)(447,497)
Current year change80,172 — (181)79,991 
Reclassification to retained earnings 90,814 — — 90,814 
Balance, December 31, 2023$(275,678)$(798)$(216)$(276,692)
During fiscal year 2023, the Company transferred $90.8 million from cumulative translation adjustments in AOCI to the gain on sale in the consolidated statement of operations as a result of the sale of the Business.
Stock Repurchases:
On July 22, 2022, the Company’s Board of Directors (the “Board”) authorized the Company to repurchase shares of common stock for an aggregate amount up to $300.0 million under a stock repurchase program (the “Repurchase Program”). On April 27, 2023, the Repurchase Program was terminated by the Board and the Board authorized the Company to repurchase shares of common stock for an aggregate amount up to $600.0 million under a new stock repurchase program (the “New Repurchase Program”). The New Repurchase Program will expire on April 26, 2025 unless terminated earlier by the Board and may be suspended or discontinued at any time. During fiscal year 2023, the Company repurchased 1,004,544 shares of common stock under the Repurchase Program for an aggregate cost of $131.3 million. During fiscal year 2023, the Company repurchased 2,159,985 shares of common stock under the New Repurchase Program for an aggregate cost of $244.6 million. As of December 31, 2023, $355.4 million remained available for aggregate repurchases of shares under the New Repurchase Program.
In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company’s equity incentive plans. During fiscal year 2023, the Company repurchased 103,144 shares of common stock for this purpose at an aggregate cost of $13.1 million. During fiscal year 2022, the Company repurchased 115,247 shares of common stock for this purpose at an aggregate cost of $18.1 million. During fiscal year 2021, the Company repurchased 71,248 shares of common stock for this purpose at an aggregate cost of $10.5 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.
 
Dividends:
The Board declared a regular quarterly cash dividend of $0.07 per share in each quarter of fiscal years 2023, 2022 and 2021, resulting in an annual dividend rate of $0.28 per share. At December 31, 2023, the Company had accrued $8.6 million for a dividend declared in October 2023 for the fourth quarter of fiscal year 2023 that was paid in February 2024. On January 25, 2024, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year 2024 that will be payable in May 2024. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.
v3.24.0.1
Derivatives And Hedging Activities
 12 Months Ended
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivatives and Hedging Activities Derivatives and Hedging Activities
 
The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business.
In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s consolidated statements of cash flows.
Principal hedged currencies include the Chinese Renminbi, British Pound, Euro and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $412.1 million at December 31, 2023 and $476.9 million at January 1, 2023, and the fair value of these foreign currency
derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of fiscal years 2023, 2022 and 2021.
In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions and stock repurchase program, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s consolidated statements of cash flows.
During fiscal year 2018, the Company designated a portion of the 2026 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of December 31, 2023, the total notional amount of the 2026 Notes that was designated to hedge investments in foreign subsidiaries was €498.6 million. The unrealized foreign exchange losses (gains) recorded in AOCI related to the net investment hedge were $19.5 million, $(34.5) million and $(33.2) million during the fiscal years 2023, 2022 and 2021, respectively.
The Company does not expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive income (loss) into interest and other expense, net within the next twelve months.
v3.24.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
 Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of December 31, 2023.
 The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition and divestiture related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value.
 Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.
 The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2023 and January 1, 2023 classified in one of the three classifications described above:
 
 Fair Value Measurements at December 31, 2023 Using:
 Total Carrying
Value at December 31, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$13,913 $13,913 $— $— 
Foreign exchange derivative assets1,697 — 1,697 — 
Foreign exchange derivative liabilities(1,763)— (1,763)— 
Contingent consideration asset14,890 $— $— 14,890 
Contingent consideration liability(40,005)— — (40,005)
 Fair Value Measurements at January 1, 2023 Using:
 Total Carrying
Value at January 1, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$11,083 $11,083 $— $— 
Foreign exchange derivative assets2,142 — 2,142 — 
Foreign exchange derivative liabilities(1,549)— (1,549)— 
Contingent consideration liability(46,618)— — (46,618)
 
Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity, fixed-income and U.S. treasury securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities.

Marketable securities - available for sale: Includes equity and mutual fund investments measured at fair value using the quoted market prices in active markets at the reporting date.

Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company’s consolidated balance sheet on a net basis and are recorded in other assets. As of both December 31, 2023 and January 1, 2023, none of the master netting arrangements involved collateral.

Level 3 Valuation Techniques:     The Company’s Level 3 assets and liabilities are comprised of contingent consideration related to the sale of the Business (see Note 4) and acquisitions. For assets and liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 assets and liabilities.

Contingent consideration:    Contingent consideration is measured at fair value at the disposition or acquisition date using projected milestone dates, discount rates, volatility, probabilities of success and projected achievement of financial targets, including revenues of the acquired business in many instances. Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model.
The fair value of the contingent consideration asset was initially measured using a lattice model and recognized upon the sale of the Business on March 13, 2023. In accordance with the terms of the sale of the Business, the Company is entitled to receive up to $150.0 million that is contingent on the exit valuation the Sponsor and its affiliated funds receive on a sale or other capital event related to the Business. Potential valuation adjustments may be made as additional information and market factors that impact the expected exit valuation of the Business becomes available, with the impact of such adjustments being recorded in the Company’s consolidated statements of operations.
A reconciliation of the beginning and ending Level 3 asset for contingent consideration is as follows:
 (In thousands)
Balance at January 1, 2023$— 
Amount recognized upon the sale of the Business15,930 
Change in fair value (included within selling, general and administrative expenses)(1,040)
Balance at December 31, 2023$14,890 
The fair values of contingent consideration liability are routinely updated based on a collaborative effort of the Company’s regulatory, research and development, operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving proof of concept, regulatory approvals and revenue targets as compared to initial projections, the impact of market competition and market landscape shifts from non-invasive prenatal testing products, with the impact of such adjustments being recorded in the consolidated statements of operations.

As of December 31, 2023, the Company may have to pay contingent consideration, related to acquisitions with open contingency periods that are substantially all revenue-based considerations, of up to $98.0 million. The expected maximum
earnout period for acquisitions with open contingency period is 7.9 years from December 31, 2023, and the remaining weighted average expected earnout period at December 31, 2023 was 5.0 years.

A reconciliation of the beginning and ending Level 3 liabilities for contingent consideration is as follows: 
 (In thousands)
Balance at January 3, 2021$(2,953)
Additions(57,431)
Amounts paid and foreign currency translation5,507 
Change in fair value (included within selling, general and administrative expenses)(3,119)
Balance at January 2, 2022(57,996)
Additions(4,961)
Amounts paid and foreign currency translation2,562 
Purchase accounting adjustments recognized to goodwill12,400 
Change in fair value (included within selling, general and administrative expenses)1,377 
Balance at January 1, 2023(46,618)
Amounts paid and foreign currency translation9,741 
Change in fair value (included within selling, general and administrative expenses)(3,128)
Balance at December 31, 2023$(40,005)
Financial Instruments Not Recorded at Fair Value
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1.
The Company’s investments in U.S. treasury securities that are classified as held-to-maturity had a fair value of $688.7 million and a carrying value of $689.9 million as of December 31, 2023. The fair value were classified as Level 1.
The Company’s outstanding senior unsecured notes had an aggregate fair value of $3,474.5 million and aggregate carrying value of $3,889.3 million as of December 31, 2023. The Company’s outstanding senior unsecured notes had an aggregate fair value of $3,812.3 million and aggregate carrying value of $4,390.5 million as of January 1, 2023. The fair values of the outstanding senior unsecured notes were estimated using market quotes from brokers and were based on current rates offered for similar debt, which are Level 2 measurements.
The Company’s other debt facilities, including the Company’s senior unsecured revolving credit facility, had an aggregate carrying value of $10.3 million and $3.7 million as of December 31, 2023 and January 1, 2023, respectively. The carrying value approximates fair value and were classified as Level 2.
v3.24.0.1
Leases (Notes)
 12 Months Ended
Dec. 31, 2023
Disclosure Text Block [Abstract]  
Leases [Text Block] Leases
Lessee Disclosures
The Company leases certain property and equipment under operating and finance leases. The Company’s leases have remaining lease terms of less than 1 year to 26 years, some of which include options to extend the lease for up to 5 years, and some of which include options to terminate the lease within 1 year. Finance leases are not material to the Company.
The components of lease expense were as follows:
 December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Lease Cost:
Operating lease cost$47,738 $39,989 $39,516 
Supplemental cash flow information related to leases was as follows:
 December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$42,597 $37,488 $38,970 
Right-of-use assets obtained in exchange for new lease obligations:
   Operating leases10,049 55,016 12,345 
Supplemental balance sheet information related to leases was as follows:
 December 31,
2023		January 1,
2023
 (In thousands, except lease term and discount rate)
Operating Leases:
Operating lease right-of-use assets$155,083 $188,351 
Operating lease liabilities included in Accrued expenses and other current liabilities$32,906 $31,217 
Operating lease liabilities132,747 169,968 
Total operating lease liabilities$165,653 $201,185 
Weighted Average Remaining Lease Term in Years
Operating leases7.26.1
Weighted Average Remaining Discount Rate
Operating leases3.8%2.6%
Lease costs from finance leases, short-term leases, variable lease costs and sub-lease income are not material.
Future payments of operating lease liabilities as of December 31, 2023 were as follows:
 (In thousands)
2024$40,010 
202531,197 
202624,747 
202721,368 
202817,382 
2029 and thereafter56,051 
Total lease payments190,755 
Less imputed interest(25,102)
    Total $165,653 
v3.24.0.1
Industry Segment and Geographic Area Information
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Industry Segment Information Industry Segment and Geographic Area Information
The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income as adjusted for certain items. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1.
The principal products and services of the Company’s two reportable segments are:
•Life Sciences. Provides products and services targeted towards the life sciences customers.
•Diagnostics. Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, emerging market diagnostics and applied genomics.
The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
The primary financial measure by which the Company evaluates the performance of its segments is adjusted operating income, which consists of operating income plus amortization of intangible assets, adjustments to operations arising from purchase accounting (primarily adjustments to the fair value of acquired inventory that are subsequently recognized), acquisition and divestiture-related costs, and other costs that are not expected to recur or are of a non-cash nature, including primarily restructuring actions.

Revenue and operating income from continuing operations by reportable segment are shown in the table below for the fiscal years ended: 
December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Revenues
Life Sciences$1,292,340 $1,292,909 $897,718 
Diagnostics1,459,058 2,019,727 2,932,738 
Revenue purchase accounting adjustments(827)(814)(2,648)
Total revenues$2,750,571 $3,311,822 $3,827,808 
Segment Operating Income
Life Sciences$489,349 $503,243 $281,602 
Diagnostics320,928 781,985 1,432,769 
Corporate(40,417)(73,431)(77,364)
Subtotal reportable segments769,860 1,211,797 1,637,007 
Amortization of intangible assets(365,113)(370,638)(256,569)
Purchase accounting adjustments(5,956)(45,681)(40,993)
Acquisition and divestiture-related costs(69,159)(39,826)(62,760)
Asset impairment— — (3,767)
Significant litigation matters and settlements(12)627 (103)
Significant environmental matters(2,457)— — 
Restructuring and other, net(26,601)(13,580)(14,358)
Operating income from continuing operations300,562 742,699 1,258,457 
Interest and other expense, net117,586 90,862 54,875 
Income from continuing operations before income taxes$182,976 $651,837 $1,203,582 
Additional information relating to the Company’s reportable segments is as follows for the three fiscal years ended December 31, 2023:
 Depreciation and Amortization ExpenseCapital Expenditures
 December 31,
2023		January 1,
2023		January 2,
2022		December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)(In thousands)
Life Sciences$276,118 $263,698 $94,700 $35,335 $41,532 $27,818 
Diagnostics153,099 161,394 214,178 39,894 40,671 57,206 
Corporate2,552 1,908 2,565 6,139 3,429 996 
Continuing operations$431,769 $427,000 $311,443 $81,368 $85,632 $86,020 
 Total Assets
 December 31,
2023		January 1,
2023
 (In thousands)
Life Sciences$8,401,851 $8,330,045 
Diagnostics4,136,305 3,991,659 
Corporate1,026,509 114,447 
Current and long-term assets of discontinued operations— 1,693,704 
Total assets$13,564,665 $14,129,855 
The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 31, 2023 and net long-lived assets based on physical location as of December 31, 2023 and January 1, 2023:
 Revenue
 December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
U.S.$1,117,654 $1,546,520 $1,682,294 
International:
China454,426 476,366 449,588 
United Kingdom125,419 136,017 357,911 
Other international1,053,072 1,152,919 1,338,015 
Total international1,632,917 1,765,302 2,145,514 
Total revenue$2,750,571 $3,311,822 $3,827,808 
 
 
Net Long-Lived Assets(1)
 December 31,
2023		January 1,
2023
 (In thousands)
U.S.$317,226 $311,661 
International:
Germany158,228 147,766 
China59,602 68,072 
Other international223,820 216,235 
Total international441,650 432,073 
Total net long-lived assets$758,876 $743,734 
(1) Long-lived assets consist of property and equipment, net, operating lease right-of-use assets, rental equipment, software and other long-term assets.
v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Pay vs Performance Disclosure      
Net income $ 693,094 $ 569,179 $ 943,157
v3.24.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement During the three months ended December 31, 2023, none of our directors or officers adopted a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as the terms are defined in Item 408(a) of Regulation S-K.
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.0.1
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Consolidation [Policy Text Block] The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In March 2023, the Company completed the previously announced sale of certain assets and the equity interests of certain entities constituting the Company’s Applied, Food and Enterprise Services businesses (the “Business”). The Business is reported for all periods as discontinued operations in the Company’s consolidated financial statements.
Fiscal Periods [Policy Text Block] The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a
52/53-week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 31, 2023 (“fiscal year 2023”), January 1, 2023 (“fiscal year 2022”) and January 2, 2022 (“fiscal year 2021”) included 52 weeks.
Accounting Policies and Estimates [Policy Text Block]
Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Revenue Recognition [Policy Text Block] Revenue Recognition:
Inventories [Policy Text Block]
Inventories: Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements.
Income Taxes [Policy Text Block]
Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not.
The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present
related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense.
The Company is subject to the Global Intangible Low Taxed Income (“GILTI”) tax in the U.S. The Company elected to treat taxes on future GILTI inclusions in U.S. taxable income as a current period expense when incurred.
The Company uses the portfolio approach for releasing income tax effects from accumulated other comprehensive income.
Property, Plant and Equipment [Policy Text Block]
Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements - estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 8 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed.
Change in Accounting for Pension and Other Postretirement Benefits [Policy Text Block] Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company’s fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds.
Translation of Foreign Currencies [Policy Text Block] Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive income (“AOCI”), a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net
Business Combinations [Policy Text Block]
Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses. Measurement period adjustments are made in the period in which the amounts are determined, and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.
Goodwill and Other Intangible Assets [Policy Text Block]
Goodwill and Other Intangible Assets:  The Company’s intangible assets consist of (i) goodwill, which is not being amortized; and (ii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives.
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values.
Stock-Based Compensation [Policy Text Block]
Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model or the quoted price of the Company’s stock on the grant
date. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock.
Marketable Securities and Investments [Policy Text Block] Marketable Securities and Investments:  Investments in debt securities that are classified as available for sale are recorded at fair value with unrealized gains and losses included in AOCI until realized. Investments in debt securities that are classified as held-to-maturity are recorded at amortized cost. Investments in equity securities are recorded at fair values with unrealized holding gains and losses included in earnings. Investments in equity securities without a readily determinable fair values are carried at cost minus impairment, if any. When an observable price change in orderly transactions for the identical or a similar investment of the same issuer has occurred, the Company elects to carry those equity investments at fair value as of the date that the observable transaction occurred.
Cash Flows [Policy Text Block]
Cash and Cash Equivalents: The Company considers all highly liquid, unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.
Environmental Matters [Policy Text Block]
Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.
Research and Development Expense, Policy [Policy Text Block] Research and Development: Research and development costs are expensed as incurred.
Restructuring Charges [Policy Text Block] Restructuring and Other Costs: Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. The Company recorded restructuring charges, included in selling, general and administrative expenses in the consolidated statements of operations, of $26.6 million, $13.6 million and $14.4 million primarily associated with workforce reductions during fiscal years 2023, 2022 and 2021, respectively. The Company expects severance payments will be substantially completed during fiscal year 2024
New Accounting Pronouncement or Change in Accounting Principle, Description
Comprehensive Income:  Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.
Derivative Instruments and Hedging [Policy Text Block]
Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting.
For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive income (loss) and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements.
The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold.
Leases: Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized based on the present value of the remaining lease payments over the lease term. When the Company’s lease did not provide an implicit rate, the Company used its incremental borrowing rate in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.
The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component.
The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statements of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred.
As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under Accounting Standards Codification 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with Accounting Standards Codification 842, Leases (“ASC 842”).
Description of New Accounting Pronouncements Not yet Adopted [Text Block]
Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 will require public entities to disclose on an annual basis a tabular reconciliation using both percentages and amounts, broken out into specific categories with certain reconciling items at or above 5% of the statutory (i.e. expected) tax further broken out by nature and/or jurisdiction. ASU 2023-09 requires all entities to disclose on an annual basis the amount of income taxes paid (net of refunds received), disaggregated between federal (national), state/local and foreign, and amounts paid to an individual jurisdiction when 5% or more of the total income taxes paid. The guidance is required to be applied on a prospective basis; retrospective application is permitted. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. Although the guidance only requires additional disclosures, the Company is in the process of determining the impact of this guidance to its income tax disclosures.
In November 2023, t
v3.24.0.1
Business Combinations and Asset Purchases (Tables)
 12 Months Ended
Dec. 31, 2023
Business Acquisition [Line Items]  
Business Acquisition, Pro Forma Information [Table Text Block] The following unaudited pro forma information presents the combined financial results for the Company and BioLegend as if the acquisition of BioLegend had been completed at the beginning of fiscal year 2020:
January 2,
2022
(In thousands, except per share data)
Pro Forma Statement of Operations Information:
Revenue$4,056,122 
Income from continuing operations947,387 
Basic earnings per share:
Income from continuing operations$7.27 
Diluted earnings per share:
Income from continuing operations$7.25 
Fair Values of the Business Combinations and Allocations for the Acquisitions Completed
The total purchase price for the acquisitions in fiscal year 2021 has been allocated to the estimated fair value of assets acquired and liabilities assumed as follows:
Final
BioLegendOther
(In thousands)
Fair value of business combinations:
Cash payments$3,336,115 $1,128,584 
Common stock issued2,638,369 — 
Other liability6,857 2,910 
Contingent consideration— 45,031 
Working capital and other adjustments— 183 
Less: cash acquired(292,377)(195,010)
Total$5,688,964 $981,698 
Identifiable assets acquired and liabilities assumed:
Current assets$184,704 $71,840 
Property, plant and equipment147,200 26,507 
Other assets9,330 15,527 
Identifiable intangible assets:
Core technology and clone library782,400 290,089 
Trade names and patents38,000 39,476 
Licenses8,979 — 
Customer relationships and backlog1,714,800 141,670 
Goodwill3,509,931 545,262 
Deferred taxes(668,919)(80,923)
Deferred revenue— (1,197)
Debt assumed— (4,628)
Liabilities assumed(37,461)(61,925)
Total$5,688,964 $981,698 
v3.24.0.1
Revenue from Contract with Customer (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue [Table Text Block]
In the following tables, revenue is disaggregated by primary geographical market and major good and service lines.
Reportable Segments
For the fiscal year ended
December 31, 2023January 1, 2023January 2, 2022
Life
 Sciences		DiagnosticsTotalLife SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$671,738 $543,875 $1,215,613 $683,170 $979,473 $1,662,643 $444,459 $1,362,213 $1,806,672 
Europe308,567 438,457 747,024 297,468 534,343 831,811 234,334 982,476 1,216,810 
Asia312,035 475,899 787,934 312,271 505,097 817,368 217,076 587,250 804,326 
$1,292,340 $1,458,231 $2,750,571 $1,292,909 $2,018,913 $3,311,822 $895,869 $2,931,939 $3,827,808 
Major goods/service lines
Life Sciences reagents$732,789 $— $732,789 $691,344 $— $691,344 $399,518 $— $399,518 
Life Sciences instruments381,262 — 381,262 405,554 — 405,554 329,584 — 329,584 
Life Sciences software178,289 — 178,289 196,011 — 196,011 166,767 — 166,767 
Reproductive health— 501,302 501,302 — 516,574 516,574 — 514,863 514,863 
Applied genomics— 228,443 228,443 — 393,602 393,602 — 619,357 619,357 
Immunodiagnostics— 728,486 728,486 — 1,108,737 1,108,737 — 1,797,719 1,797,719 
$1,292,340 $1,458,231 $2,750,571 $1,292,909 $2,018,913 $3,311,822 $895,869 $2,931,939 $3,827,808 
Contract with Customer, Contract Asset, Contract Liability, and Receivable
Contract balances were as follows:
December 31, 2023January 1, 2023
(In thousands)
Contract assets$52,648 $56,631 
Contract liabilities(22,504)(30,133)
v3.24.0.1
Discontinued Operations (Tables)
 12 Months Ended
Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] The following table summarizes the results of discontinued operations which are presented as income from discontinued operations in the Company’s consolidated statements of operations:
 December 31, 2023January 1, 2023January 2, 2022
 (In thousands)
Revenue$176,324 $1,298,376 $1,239,361 
Cost of revenue125,219 859,330 822,048 
Selling, general and administrative expenses78,613 306,032 268,760 
Research and development expenses10,434 64,605 74,632 
Operating (loss) income(37,942)68,409 73,921 
Other income:
Gain on sale811,472 — — 
Other (expense) income, net(49)5,195 2,383 
Total other income811,423 5,195 2,383 
Income from discontinued operations before income taxes773,481 73,604 76,304 
Provision for income tax259,890 17,101 22,583 
Income from discontinued operations$513,591 $56,503 $53,721 
Schedule of Operating and Investing non-cash items from discontinued operations [Table Text Block]
The following operating and investing items from discontinued operations were as follows for the fiscal years ended:
December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Depreciation
$— $8,011 $12,897 
Amortization
— 16,984 33,664 
Capital expenditures1,292 10,670 13,868 
Schedule of carrying amounts of major classes of assets and liabilities included in discontinued operations [Table Text Block]
The table below provides a reconciliation of the carrying amounts of the major classes of assets and liabilities of the discontinued operations to the amounts presented separately in the consolidated balance sheet at January 1, 2023.
January 1, 2023
 (In thousands)
Cash and cash equivalents$14,999 
Accounts receivable343,064 
Inventories210,367 
Other current assets32,063 
Total current assets600,493 
Property, plant and equipment, net60,983 
Operating lease right-of-use assets41,487 
Intangible assets, net202,850 
Goodwill772,812 
Other assets, net15,079 
    Total long-term assets
1,093,211 
Total assets of discontinued operations
$1,693,704 
Accounts payable29,912 
Accrued expenses and other current liabilities161,260 
    Total current liabilities191,172 
Deferred taxes and long-term liabilities46,046 
Operating lease liabilities35,647 
    Total long-term liabilities81,693 
Total liabilities of discontinued operations$272,865 
v3.24.0.1
Income Taxes (Tables) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Income Tax Disclosure [Abstract]    
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
The components of income from continuing operations before income taxes were as follows for the fiscal years ended:
 
December 31,
2023		January 1,
2023		January 2,
2022
(In thousands)
U.S.$51,314 $326,438 $547,705 
Non-U.S.131,662 325,399 655,877 
Total$182,976 $651,837 $1,203,582 
  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
The components of the provision for income taxes on continuing operations were as follows:
 
Current
Expense		Deferred 
Expense
(Benefit)		Total
(In thousands)
Fiscal year ended December 31, 2023
Federal$39,800 $(60,845)$(21,045)
State9,183 (19,619)(10,436)
Non-U.S.78,154 (43,200)34,954 
Total$127,137 $(123,664)$3,473 
Fiscal year ended January 1, 2023
Federal$115,436 $(45,246)$70,190 
State27,757 (16,139)11,618 
Non-U.S.101,891 (44,538)57,353 
Total$245,084 $(105,923)$139,161 
Fiscal year ended January 2, 2022
Federal$154,905 $(37,858)$117,047 
State53,961 3,602 57,563 
Non-U.S.160,608 (21,072)139,536 
Total$369,474 $(55,328)$314,146 
  
Schedule of Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations [Table Text Block]
The total provision for income taxes included in the consolidated financial statements is as follows for the fiscal years ended: 
December 31,
2023		January 1,
2023		January 2,
2022
(In thousands)
Continuing operations$3,473 $139,161 $314,146 
Discontinued operations259,890 17,101 22,583 
Total$263,363 $156,262 $336,729 
  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended:
 
December 31,
2023		January 1,
2023		January 2,
2022
(In thousands)
Tax at statutory rate$38,346 $136,886 $252,752 
Non-U.S. rate differential, net(18,479)(5,221)(33,847)
U.S. taxation of multinational operations(4,594)22,102 7,964 
State income taxes, net(265)7,820 36,832 
Impact of rate changes(12,795)— 14,031 
Prior year tax matters3,971 (10,160)1,850 
Effect of stock compensation2,225 845 (2,187)
General business tax credits(4,718)(7,132)(2,715)
Transfer pricing matters(6,725)— — 
Change in valuation allowance6,772 4,964 (179)
Effect of foreign repatriations(4,737)(4,940)37,147 
Other, net4,472 (6,003)2,498 
Total$3,473 $139,161 $314,146 
  
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities were as follows: 
December 31,
2023		January 1,
2023
(In thousands)
Deferred tax assets:
Inventory$12,934 $17,920 
Reserves and accruals63,711 70,912 
Accrued compensation18,339 23,868 
Net operating loss and credit carryforwards133,919 117,953 
Accrued pension11,089 11,653 
Restructuring reserve1,588 1,640 
Deferred revenue17,539 22,644 
Capitalized research and development expenses47,188 44,922 
Operating lease liabilities29,319 43,547 
Unrealized foreign exchange loss
12,502 11,158 
All other, net1,610 841 
Total deferred tax assets349,738 367,058 
Deferred tax liabilities:
Postretirement health benefits(4,452)(4,379)
Depreciation and amortization(784,925)(916,581)
Operating lease right-of-use assets(26,301)(39,281)
Prepaid expenses(349)(3,515)
Deferred tax liability on foreign earnings(17,587)(15,782)
Total deferred tax liabilities(833,614)(979,538)
Valuation allowance(84,626)(96,681)
Net deferred tax liabilities$(568,502)$(709,161)
  
Components of net deferred tax asset recognized [Table Text Block]
The components of net deferred tax liabilities were recognized in the consolidated balance sheets as follows:
December 31,
2023		January 1,
2023
(In thousands)
Other assets, net$8,158 $18,527 
Deferred taxes and other long-term liabilities(576,660)(727,688)
Total$(568,502)$(709,161)
  
Deferred tax assets, other assets, net $ 8,158 $ 18,527
Deferred tax liabilities, Long-term liabilities (576,660) (727,688)
Deferred Tax Liabilities, Net $ (568,502) $ (709,161)
v3.24.0.1
Earnings Per Share (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended:
December 31,
2023		January 1,
2023		January 2,
2022
(In thousands)
Number of common shares—basic124,704 126,155 116,165 
Effect of dilutive securities:
Stock options108 249 391 
Restricted stock awards— 22 118 
Number of common shares—diluted124,812 126,426 116,674 
Number of potentially dilutive securities excluded from calculation due to antidilutive impact1,089 611 487 
v3.24.0.1
Accounts Receivable, Net Accounts Receivable, Net (Tables)
 12 Months Ended
Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
Accounts receivable, net consisted of the following:
 
December 31,
2023		January 1,
2023
(In thousands)
Accounts receivable, net$632,811 $612,780 
Long-term accounts receivable, net, included in Other assets, net29,593 34,040 
Total accounts receivable, net$662,404 $646,820 
Accounts Receivable, Allowance for Credit Loss
Reserves for credit losses consisted of the following:
Balance at Beginning of YearProvisionsCharges/
Write-offs
Other(1)
Balance at End
of Year
  (In thousands)
Year ended January 2, 2022$33,497 $6,854 $(2,198)$101 $38,254 
Year ended January 1, 202338,254 9,857 (9,672)(896)37,543 
Year ended December 31, 202337,543 9,067 (3,559)329 43,380 
v3.24.0.1
Inventories, Net (Tables)
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of Net Inventories
Inventories, net consisted of the following:
 
December 31,
2023		January 1,
2023
(In thousands)
Raw materials$197,268 $190,640 
Work in progress69,176 68,206 
Finished goods161,618 146,616 
Total inventories, net$428,062 $405,462 
v3.24.0.1
Property, Plant and Equipment, Net (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment, Net [Abstract]  
Property, Plant and Equipment [Table Text Block]
Property, plant and equipment consisted of the following:
December 31,
2023		January 1,
2023
(In thousands)
At cost:
Land$29,635 $28,340 
Building and leasehold improvements358,380 346,164 
Machinery and equipment595,124 482,639 
Total property, plant and equipment983,139 857,143 
Accumulated depreciation(473,485)(374,193)
Total property, plant and equipment, net$509,654 $482,950 
v3.24.0.1
Marketable Securities and Investments (Tables)
 12 Months Ended
Dec. 31, 2023
Marketable Securities [Abstract]  
Schedule of Investments, Noncurrent [Table Text Block] Investments consisted of the following:
 
December 31,
2023		January 1,
2023
(In thousands)
Marketable securities - held to maturity (current)$689,916 $— 
Marketable securities - available for sale13,913 11,083 
Equity investments57,206 54,503 
Notes receivables and other investments12,280 42,500 
$773,315 $108,086 
Equity Securities without Readily Determinable Fair Value Equity investments, which are included in Other assets, net, as of December 31, 2023 and January 1, 2023 consisted of the following:
December 31,
2023		January 1,
2023
(In thousands)
Equity investments, carried at cost minus impairment, if any$47,260 $50,654 
Equity investments, carried at fair value9,946 3,849 
$57,206 $54,503 
v3.24.0.1
Goodwill and Intangible Assets, Net (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in the Carrying Amount of Goodwill
The changes in the carrying amount of goodwill for fiscal years 2023 and 2022 are as follows:
Life SciencesDiagnosticsConsolidated
(In thousands)
Balance at January 2, 2022$4,656,769 $1,970,350 $6,627,119 
Foreign currency translation(98,268)(41,617)(139,885)
Acquisitions, earnouts and measurement period adjustments(6,926)1,460 (5,466)
Balance at January 1, 20234,551,575 1,930,193 6,481,768 
Foreign currency translation36,363 15,419 51,782 
Balance at December 31, 2023$4,587,938 $1,945,612 $6,533,550 
Identifiable Intangible Asset Balances
Identifiable intangible asset balances at December 31, 2023 and January 1, 2023 were as follows:
December 31,
2023		January 1,
2023
(In thousands)
Patents$27,811 $28,020 
Less: Accumulated amortization(26,072)(26,055)
Net patents1,739 1,965 
Trade names and trademarks145,542 149,453 
Less: Accumulated amortization(73,781)(63,590)
Net trade names and trademarks71,761 85,863 
Licenses27,018 62,614 
Less: Accumulated amortization(16,551)(54,254)
Net licenses10,467 8,360 
Core technology1,582,458 1,556,740 
Less: Accumulated amortization(607,814)(449,689)
Net core technology974,644 1,107,051 
Customer relationships2,842,531 2,943,761 
Less: Accumulated amortization(878,821)(775,104)
Net customer relationships1,963,710 2,168,657 
In-process research and development— 5,278 
Net amortizable intangible assets$3,022,321 $3,377,174 
v3.24.0.1
Debt (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Maturities of Long-term Debt [Table Text Block]
The following table summarizes the maturities of the Company’s indebtedness as of December 31, 2023: 
(In thousands)
2024$723,291 
2025206 
2026553,570 
202792 
2028500,046 
2029 and thereafter2,150,000 
Total debt payments3,927,205 
Less unamortized discount and debt issuance costs(27,563)
Total$3,899,642 
Schedule of Debt The Company’s debt consisted of the following:
December 31, 2023
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(1,966)$(1,966)
€500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”)553,450 (1,438)(1,279)550,733 
1.900% Senior Unsecured Notes due in 2028 (“2028 Notes”)
500,000 (250)(3,024)496,726 
3.3% Senior Unsecured Notes due in 2029 (“2029 Notes”)850,000 (1,727)(4,781)843,492 
2.55% Senior Unsecured Notes due in March 2031 (“March 2031 Notes”)400,000 (101)(2,638)397,261 
2.250% Senior Unsecured Notes due in September 2031 (“September 2031 Notes”)
500,000 (1,210)(3,568)495,222 
3.625% Senior Unsecured Notes due in 2051 (“2051 Notes”)400,000 (4)(4,158)395,838 
Other Debt Facilities, non-current464 — — 464 
Total Long-Term Debt3,203,914 (4,730)(21,414)3,177,770 
Current Portion of Long-term Debt:
0.850% Senior Unsecured Notes due in 2024 (“2024 Notes”)
711,479 (118)(1,301)710,060 
Other Debt Facilities, current11,812 — — 11,812 
Total Current Portion of Long-Term Debt723,291 (118)(1,301)721,872 
Total Debt$3,927,205 $(4,848)$(22,715)$3,899,642 
January 1, 2023
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(2,641)$(2,641)
2024 Notes771,659 (283)(3,136)768,240 
2026 Notes533,950 (1,902)(1,779)530,269 
2028 Notes500,000 (301)(3,631)496,068 
2029 Notes850,000 (2,000)(5,537)842,463 
March 2031 Notes400,000 (114)(2,978)396,908 
September 2031 Notes500,000 (1,353)(3,991)494,656 
2051 Notes400,000 (4)(4,260)395,736 
Other Debt Facilities, non-current1,648 — — 1,648 
Total Long-Term Debt3,957,257 (5,957)(27,953)3,923,347 
Current Portion of Long-term Debt:
0.550% Senior Unsecured Notes due in September 2023 (“2023 Notes”)467,138 (63)(867)466,208 
Other Debt Facilities, current4,721 — — 4,721 
Total Current Portion of Long-Term Debt471,859 (63)(867)470,929 
Total Debt$4,429,116 $(6,020)$(28,820)$4,394,276 
v3.24.0.1
Accrued Expenses and Other Current Liabilities (Tables)
 12 Months Ended
Dec. 31, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Schedule of Accrued Liabilities [Table Text Block]
Accrued expenses and other current liabilities consisted of the following:
 
December 31,
2023		January 1,
2023
(In thousands)
Payroll and incentives$50,526 $52,331 
Employee benefits43,279 51,983 
Deferred revenue135,555 135,531 
Federal, non-U.S. and state income taxes88,159 45,625 
Operating lease liabilities
32,906 31,217 
Other accrued operating expenses174,045 211,176 
Total accrued expenses and other current liabilities$524,470 $527,863 
v3.24.0.1
Employee Benefit Plans (Tables) - Pension Plans, Defined Benefit
 12 Months Ended
Dec. 31, 2023
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
Components of Net Periodic Benefit Cost (Credit) Net periodic pension cost for U.S. and non-U.S. plans included the following components for fiscal years ended:
December 31,
2023		January 1,
2023		January 2,
2022
(In thousands)
Service and administrative costs$5,736 $6,331 $5,174 
Interest cost19,585 10,751 9,440 
Expected return on plan assets(14,600)(22,056)(24,417)
Actuarial losses (gains)9,341 (23,706)(19,514)
Net periodic pension cost (credit)$20,062 $(28,680)$(29,317)
Schedule of Net Funded Status
The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 31, 2023 and January 1, 2023.
 December 31, 2023January 1, 2023
Non-U.S.U.S.Non-U.S.U.S.
(In thousands)
Actuarial present value of benefit obligations:
Accumulated benefit obligations$227,174 $208,505 $207,503 $231,492 
Change in benefit obligations:
Projected benefit obligations at beginning of year$207,955 $231,492 $339,390 $299,826 
Service and administrative costs4,011 1,725 4,956 1,375 
Interest cost8,843 10,742 3,671 7,080 
Benefits paid and plan expenses(15,061)(39,895)(14,978)(19,870)
Benefit obligation classified in discontinued operations— — (8,261)— 
Actuarial losses (gains)12,871 4,441 (88,724)(56,919)
Effect of exchange rate changes8,960 — (28,099)— 
Projected benefit obligations at end of year$227,579 $208,505 $207,955 $231,492 
Change in plan assets:
Fair value of plan assets at beginning of year$106,741 $216,748 $181,189 $290,116 
Actual return on plan assets7,094 15,478 (46,383)(53,498)
Benefits paid and plan expenses(15,061)(39,895)(14,978)(19,870)
Employer’s contributions7,606 10,000 6,572 — 
Effect of exchange rate changes5,925 — (19,659)— 
Fair value of plan assets at end of year$112,305 $202,331 $106,741 $216,748 
Net liabilities recognized in the consolidated balance sheets$(115,274)$(6,174)$(101,214)$(14,744)
Net amounts recognized in the consolidated balance sheets consist of:
Other assets$19,540 $— $19,521 $— 
Current liabilities(6,899)— (6,568)— 
Long-term liabilities(127,915)(6,174)(114,167)(14,744)
Net liabilities recognized in the consolidated balance sheets$(115,274)$(6,174)$(101,214)$(14,744)
Actuarial assumptions as of the year-end measurement date:
Discount rate3.69 %4.54 %4.12 %4.84 %
Rate of compensation increase3.19 %None3.16 %None
Actuarial assumptions used to determine net periodic pension cost during the year were as follows:
December 31, 2023January 1, 2023January 2, 2022
Non-U.S.U.S.Non-U.S.U.S.Non-U.S.U.S.
Discount rate4.12 %4.84 %1.41 %2.44 %0.92 %2.21 %
Rate of compensation increase3.16 %None2.78 %None2.78 %None
Expected rate of return on assets3.92 %4.80 %1.11 %7.25 %2.10 %7.25 %
Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]
The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets:
December 31,
2023		January 1,
2023
(In thousands)
Pension Plans with Projected Benefit Obligations in Excess of Plan Assets
Projected benefit obligations$134,814 $120,736 
Fair value of plan assets— — 
Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets
Accumulated benefit obligations$134,409 $120,283 
Fair value of plan assets— — 
Schedule of Allocation of Plan Assets Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 31, 2023 and January 1, 2023, and target asset allocations for fiscal year 2024 are as follows:
 Target AllocationPercentage of Plan Assets at
December 29, 2024December 31, 2023January 1, 2023
Asset CategoryNon-U.S.U.S.Non-U.S.U.S.Non-U.S.U.S.
Equity securities0-5%0-10%— %6 %— %44 %
Debt securities0-5%90-100%— %94 %— %56 %
Other95-100%0-10%100%— %100 %— %
Total100 %100 %100 %100 %100 %100 %
Schedule of Changes in Fair Value of Plan Assets
The fair value of the Company’s pension plan assets as of December 31, 2023 and January 1, 2023 by asset category, classified in the three levels of inputs described in Note 20 to the consolidated financial statements are as follows:
 
 Fair Value Measurements at December 31, 2023 Using:
Total Carrying
Value at
December 31, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash and cash equivalents$14,223 $14,223 $— $— 
Equity securities:
U.S. large-cap7,011 7,011 — — 
International large-cap value2,350 2,350 — — 
Emerging markets growth1,068 1,068 — — 
Fixed income securities:
Corporate and U.S. debt instruments189,318 65,228 124,090 — 
Other types of investments:
Foreign liability driven instrument100,666 — — 100,666 
Total assets measured at fair value$314,636 $89,880 $124,090 $100,666 
 Fair Value Measurements at January 1, 2023 Using:
Total Carrying
Value at
January 1, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash$14,483 $14,483 $— $— 
Equity Securities:
U.S. large-cap61,680 61,680 — — 
International large-cap value20,148 20,148 — — 
Emerging markets growth9,902 9,902 — — 
Fixed income securities:
Corporate and U.S. debt instruments105,126 36,346 68,780 — 
Corporate bonds17,088 — 17,088 — 
Other types of investments:
Foreign liability driven instrument95,062 — — 95,062 
Total assets measured at fair value$323,489 $142,559 $85,868 $95,062 
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets
A reconciliation of the beginning and ending Level 3 foreign liability driven investments is as follows:
 
(In thousands)
Balance at January 2, 2022$165,680 
Pension benefits paid(6,639)
Foreign exchange losses(18,411)
Return on plan assets(45,568)
Balance at January 1, 202395,062 
Pension benefits paid(6,051)
Foreign exchange gains5,957 
Return on plan assets5,698 
Balance at December 31, 2023$100,666 
Schedule of Expected Benefit Payments
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
 
Non-U.S.U.S.
(In thousands)
2024$12,331 $18,882 
202512,598 18,583 
202612,720 18,240 
202712,673 17,864 
202812,914 17,408 
2029-203364,702 77,782 
v3.24.0.1
Stock Plans (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Total Compensation Recognized Related to Outstanding Equity Awards
The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units, performance units and stock grants, included in the Company’s consolidated statements of operations:
 December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Cost of product and service revenue$4,224 $7,459 $3,193 
Research and development expenses5,276 6,799 2,393 
Selling, general and administrative expenses31,910 37,260 24,089 
Total stock-based compensation expense$41,410 $51,518 $29,675 
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended:
 
December 31,
2023		January 1,
2023		January 2,
2022
Risk-free interest rate4.1 %2.3 %0.9 %
Expected dividend yield0.2 %0.2 %0.2 %
Expected lives5 years5 years5 years
Expected stock volatility32.7 %28.5 %27.3 %
Summary of Stock Option Activity
The following table summarizes stock option activity for the fiscal year ended December 31, 2023:
 
 Number
of
Shares		Weighted-
Average Exercise
Price
 (Shares in thousands)
Outstanding at beginning of year1,048 $132.32 
Granted168 128.35 
Exercised(58)76.12 
Canceled(49)154.37 
Forfeited(36)146.13 
Outstanding at end of year1,073 $133.28 
Exercisable at end of year693 $125.06 
Summary of Restricted Stock Award Activity
The following table summarizes restricted stock award activity for the fiscal year ended December 31, 2023:
 
Number
of
Shares		Weighted-
Average
Grant-
Date Fair
Value
 (Shares in thousands)
Nonvested at beginning of year453 $152.79 
Granted139 128.79 
Vested(221)142.69 
Forfeited(30)147.80 
Nonvested at end of year341 $149.98 
v3.24.0.1
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive income (loss) consisted of the following:
 
Foreign
Currency
Translation
Adjustment,
net of tax		Unrecognized
Prior Service
Costs, net of
tax		Unrealized
(Losses)
Gains on
Securities,
net of tax		Accumulated
Other
Comprehensive
Income (Loss)
 (In thousands)
Balance, January 3, 2021$(30,937)$(747)$(277)$(31,961)
Current year change(130,873)(95)237 (130,731)
Balance, January 2, 2022(161,810)(842)(40)(162,692)
Current year change(284,854)44 5 (284,805)
Balance, January 1, 2023(446,664)(798)(35)(447,497)
Current year change80,172 — (181)79,991 
Reclassification to retained earnings 90,814 — — 90,814 
Balance, December 31, 2023$(275,678)$(798)$(216)$(276,692)
v3.24.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2023 and January 1, 2023 classified in one of the three classifications described above:
 
 Fair Value Measurements at December 31, 2023 Using:
 Total Carrying
Value at December 31, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$13,913 $13,913 $— $— 
Foreign exchange derivative assets1,697 — 1,697 — 
Foreign exchange derivative liabilities(1,763)— (1,763)— 
Contingent consideration asset14,890 $— $— 14,890 
Contingent consideration liability(40,005)— — (40,005)
 Fair Value Measurements at January 1, 2023 Using:
 Total Carrying
Value at January 1, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$11,083 $11,083 $— $— 
Foreign exchange derivative assets2,142 — 2,142 — 
Foreign exchange derivative liabilities(1,549)— (1,549)— 
Contingent consideration liability(46,618)— — (46,618)
Reconciliation of Beginning and Ending Level 3 Net Liabilities
A reconciliation of the beginning and ending Level 3 liabilities for contingent consideration is as follows: 
 (In thousands)
Balance at January 3, 2021$(2,953)
Additions(57,431)
Amounts paid and foreign currency translation5,507 
Change in fair value (included within selling, general and administrative expenses)(3,119)
Balance at January 2, 2022(57,996)
Additions(4,961)
Amounts paid and foreign currency translation2,562 
Purchase accounting adjustments recognized to goodwill12,400 
Change in fair value (included within selling, general and administrative expenses)1,377 
Balance at January 1, 2023(46,618)
Amounts paid and foreign currency translation9,741 
Change in fair value (included within selling, general and administrative expenses)(3,128)
Balance at December 31, 2023$(40,005)
v3.24.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Lease, Cost [Table Text Block]
The components of lease expense were as follows:
 December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Lease Cost:
Operating lease cost$47,738 $39,989 $39,516 
Supplemental Cash Flow Information Related To Leases [Table Text Block]
Supplemental cash flow information related to leases was as follows:
 December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$42,597 $37,488 $38,970 
Right-of-use assets obtained in exchange for new lease obligations:
   Operating leases10,049 55,016 12,345 
Supplemental Balance Sheet Information Related To Leases [Table Text Block]
Supplemental balance sheet information related to leases was as follows:
 December 31,
2023		January 1,
2023
 (In thousands, except lease term and discount rate)
Operating Leases:
Operating lease right-of-use assets$155,083 $188,351 
Operating lease liabilities included in Accrued expenses and other current liabilities$32,906 $31,217 
Operating lease liabilities132,747 169,968 
Total operating lease liabilities$165,653 $201,185 
Weighted Average Remaining Lease Term in Years
Operating leases7.26.1
Weighted Average Remaining Discount Rate
Operating leases3.8%2.6%
Lease costs from finance leases, short-term leases, variable lease costs and sub-lease income are not material.
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
Future payments of operating lease liabilities as of December 31, 2023 were as follows:
 (In thousands)
2024$40,010 
202531,197 
202624,747 
202721,368 
202817,382 
2029 and thereafter56,051 
Total lease payments190,755 
Less imputed interest(25,102)
    Total $165,653 
v3.24.0.1
Industry Segment and Geographic Area Information (Tables)
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations
Revenue and operating income from continuing operations by reportable segment are shown in the table below for the fiscal years ended: 
December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Revenues
Life Sciences$1,292,340 $1,292,909 $897,718 
Diagnostics1,459,058 2,019,727 2,932,738 
Revenue purchase accounting adjustments(827)(814)(2,648)
Total revenues$2,750,571 $3,311,822 $3,827,808 
Segment Operating Income
Life Sciences$489,349 $503,243 $281,602 
Diagnostics320,928 781,985 1,432,769 
Corporate(40,417)(73,431)(77,364)
Subtotal reportable segments769,860 1,211,797 1,637,007 
Amortization of intangible assets(365,113)(370,638)(256,569)
Purchase accounting adjustments(5,956)(45,681)(40,993)
Acquisition and divestiture-related costs(69,159)(39,826)(62,760)
Asset impairment— — (3,767)
Significant litigation matters and settlements(12)627 (103)
Significant environmental matters(2,457)— — 
Restructuring and other, net(26,601)(13,580)(14,358)
Operating income from continuing operations300,562 742,699 1,258,457 
Interest and other expense, net117,586 90,862 54,875 
Income from continuing operations before income taxes$182,976 $651,837 $1,203,582 
Schedule of Depreciation, Amortization and Capital Expenditures
Additional information relating to the Company’s reportable segments is as follows for the three fiscal years ended December 31, 2023:
 Depreciation and Amortization ExpenseCapital Expenditures
 December 31,
2023		January 1,
2023		January 2,
2022		December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)(In thousands)
Life Sciences$276,118 $263,698 $94,700 $35,335 $41,532 $27,818 
Diagnostics153,099 161,394 214,178 39,894 40,671 57,206 
Corporate2,552 1,908 2,565 6,139 3,429 996 
Continuing operations$431,769 $427,000 $311,443 $81,368 $85,632 $86,020 
Schedule of Total Assets by Segment
 Total Assets
 December 31,
2023		January 1,
2023
 (In thousands)
Life Sciences$8,401,851 $8,330,045 
Diagnostics4,136,305 3,991,659 
Corporate1,026,509 114,447 
Current and long-term assets of discontinued operations— 1,693,704 
Total assets$13,564,665 $14,129,855 
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 31, 2023 and net long-lived assets based on physical location as of December 31, 2023 and January 1, 2023:
 Revenue
 December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
U.S.$1,117,654 $1,546,520 $1,682,294 
International:
China454,426 476,366 449,588 
United Kingdom125,419 136,017 357,911 
Other international1,053,072 1,152,919 1,338,015 
Total international1,632,917 1,765,302 2,145,514 
Total revenue$2,750,571 $3,311,822 $3,827,808 
 
 
Net Long-Lived Assets(1)
 December 31,
2023		January 1,
2023
 (In thousands)
U.S.$317,226 $311,661 
International:
Germany158,228 147,766 
China59,602 68,072 
Other international223,820 216,235 
Total international441,650 432,073 
Total net long-lived assets$758,876 $743,734 
v3.24.0.1
Business Combinations and Asset Purchases (Narrative) (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
Jan. 01, 2023
USD ($)
employees
Jan. 02, 2022
USD ($)
employees
$ / shares
shares
Sep. 17, 2021
$ / shares
Business Acquisition [Line Items]        
Business Combination, Contingent Consideration, Liability, Current $ (11,000)      
Business Combination, Contingent Consideration, Liability, Noncurrent 29,000      
Business Combination, Contingent Consideration, Liability, Total $ (40,000)      
Business Combination, Contingent Consideration Arrangements, Maximum Period 7 years 10 months 24 days      
Beginning balance $ 6,533,550 $ 6,481,768 $ 6,627,119  
Business Combination, Contingent Consideration Arrangements, Weighted Average Period 5 years      
Business Combination, Acquisition Related Costs $ 69,200 $ 39,800 $ 62,800  
Analytical, Food and Enterprise Services businesses        
Business Acquisition [Line Items]        
Divestiture-related Rebranding Costs 34,300      
Divestiture-related Interest and Other Expense 19,900      
Foreign Currency Transaction Loss, before Tax 24,100      
Divestiture-related Interest Income (4,200)      
Oxford Immunotec        
Business Acquisition [Line Items]        
Entity Number of Employees | employees     275  
Nexcelom Bioscience        
Business Acquisition [Line Items]        
Entity Number of Employees | employees   130    
BioLegend [Member]        
Business Acquisition [Line Items]        
Business Acquisition, Pro Forma Revenue     $ 4,056,122  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets     184,704  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities     0  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment     147,200  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets     9,330  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net     5,688,964  
Business Acquisition, Cost of Acquired Entity, Cash Paid     3,336,115  
Business Combination, Consideration Transferred, Liabilities Incurred     $ 6,857  
Weighted average amortization period (in years)     16 years 3 months 18 days  
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual   $ 91,700    
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual     $ 25,800  
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value     0  
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments     $ 0  
Entity Number of Employees | employees     700  
Beginning balance     $ 3,509,931  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total     (668,919)  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue     0  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt     (37,461)  
Cash Acquired from Acquisition     292,400  
Cash Acquired     (292,377)  
Business Combination, Consideration Transferred     5,688,964  
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax     $ 947,387  
Business Acquisition, Pro Forma Earnings Per Share, Basic | $ / shares     $ 7,270  
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ / shares     $ 7,250  
Cash Acquired from Acquisition     $ (292,400)  
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Common Stock     $ 2,600,000  
Business Acquisition, Share Price | $ / shares       $ 187.56
Stock Issued During Period, Shares, Acquisitions | shares     14,066,799  
Business Combination, Acquisition Related Costs, Excluded From Proforma Income (Loss) From Continuing Operations     $ 43,200  
Business Combination, Bridge Financing and Debt Pre-issuance Hedging Costs, Excluded From Proforma Income (Loss) From Continuing Operations     23,300  
Business Combination, Pro Forma Information, Amortization of Acquired Intangible Assets     47,000  
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Cash     3,300,000  
Acquisition-related stock compensation expense 20,000 $ 26,500 6,900  
Acquisition-related Interest and Other Expense     18,000  
Foreign Currency Transaction Gain, before Tax     (5,400)  
Acquisition-related Bridge Financing and Debt Pre-issuance Hedging Costs     23,400  
Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]        
Business Acquisition [Line Items]        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets     71,840  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities     (4,628)  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment     26,507  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets     15,527  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net     981,698  
Business Acquisition, Cost of Acquired Entity, Cash Paid     1,128,584  
Business Combination, Consideration Transferred, Liabilities Incurred     $ 2,910  
Weighted average amortization period (in years)     12 years 4 months 24 days  
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value     $ (45,031)  
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments     183  
Beginning balance     545,262  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total     (80,923)  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue     1,197  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt     (61,925)  
Cash Acquired     (195,010)  
Business Combination, Consideration Transferred     981,698  
Sirion, Qognit, Sonovol and Prisms [Member]        
Business Acquisition [Line Items]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 98,000      
Fiscal Year 2022 Acquisitions        
Business Acquisition [Line Items]        
Weighted average amortization period (in years)   5 years    
Diagnostics [Member]        
Business Acquisition [Line Items]        
Beginning balance $ 1,945,612 $ 1,930,193 1,970,350  
United States of America, Dollars | Fiscal Year 2021 Other Acquisitions        
Business Acquisition [Line Items]        
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments     318,600  
United States of America, Dollars | Oxford Immunotec        
Business Acquisition [Line Items]        
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments     590,900  
United States of America, Dollars | Nexcelom Bioscience        
Business Acquisition [Line Items]        
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments     267,300  
United States of America, Dollars | BioLegend [Member]        
Business Acquisition [Line Items]        
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments     5,700,000  
United States of America, Dollars | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]        
Business Acquisition [Line Items]        
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments     $ 1,200,000  
United States of America, Dollars | Fiscal Year 2022 Acquisitions        
Business Acquisition [Line Items]        
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments   $ 13,300    
v3.24.0.1
Business Combinations and Asset Purchases (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 02, 2022
Dec. 31, 2023
Jan. 01, 2023
Business Acquisition [Line Items]      
Goodwill $ 6,627,119 $ 6,533,550 $ 6,481,768
BioLegend [Member]      
Business Acquisition [Line Items]      
Business Acquisition, Cost of Acquired Entity, Cash Paid 3,336,115    
Less: cash acquired 292,377    
Business Combination, Consideration Transferred 5,688,964    
Current assets 184,704    
Property, plant and equipment 147,200    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets 9,330    
Goodwill 3,509,931    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total (668,919)    
Liabilities assumed 0    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt (37,461)    
Total 5,688,964    
Business Combination, Consideration Transferred, Liabilities Incurred 6,857    
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 2,638,369    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue 0    
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value 0    
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments 0    
BioLegend [Member] | United States of America, Dollars      
Business Acquisition [Line Items]      
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments 5,700,000    
Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]      
Business Acquisition [Line Items]      
Business Acquisition, Cost of Acquired Entity, Cash Paid 1,128,584    
Less: cash acquired 195,010    
Business Combination, Consideration Transferred 981,698    
Current assets 71,840    
Property, plant and equipment 26,507    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets 15,527    
Goodwill 545,262    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total (80,923)    
Liabilities assumed (4,628)    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt (61,925)    
Total 981,698    
Business Combination, Consideration Transferred, Liabilities Incurred 2,910    
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 0    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue (1,197)    
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value 45,031    
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments 183    
Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] | United States of America, Dollars      
Business Acquisition [Line Items]      
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments 1,200,000    
Fiscal Year 2021 Other Acquisitions | United States of America, Dollars      
Business Acquisition [Line Items]      
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments 318,600    
License | BioLegend [Member]      
Business Acquisition [Line Items]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 8,979    
License | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]      
Business Acquisition [Line Items]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 0    
Customer Relationships and Backlog [Member] | BioLegend [Member]      
Business Acquisition [Line Items]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 1,714,800    
Customer Relationships and Backlog [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]      
Business Acquisition [Line Items]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 141,670    
Trade Names and Patents [Member] | BioLegend [Member]      
Business Acquisition [Line Items]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 38,000    
Trade Names and Patents [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]      
Business Acquisition [Line Items]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 39,476    
Core technology and Clone Library [Member] | BioLegend [Member]      
Business Acquisition [Line Items]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 782,400    
Core technology and Clone Library [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]      
Business Acquisition [Line Items]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 290,089    
Diagnostics [Member]      
Business Acquisition [Line Items]      
Goodwill $ 1,970,350 $ 1,945,612 $ 1,930,193
v3.24.0.1
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Narrative) (Details) (Details)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
USD ($)
segments
Jan. 01, 2023
USD ($)
Jan. 02, 2022
USD ($)
Number of Operating Segments | segments   2    
Unamortized Debt Issuance Expense   $ 22,715 $ 28,820  
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents   $ (14,048) (33,747) $ (22,926)
Fiscal Year Week Format   52    
Restructuring and other costs, net   $ 26,601 $ (13,580) $ (14,358)
Minimum [Member] | Building [Member]        
Property, Plant and Equipment, Useful Life, Maximum   10 years    
Minimum [Member] | Tools, Dies and Molds [Member]        
Property, Plant and Equipment, Useful Life, Maximum   3 years    
Maximum [Member] | Building [Member]        
Property, Plant and Equipment, Useful Life, Maximum   40 years    
Maximum [Member] | Machinery and Equipment [Member]        
Property, Plant and Equipment, Useful Life, Maximum   8 years    
Subsequent Event [Member]        
Fiscal Year Week Format 52      
v3.24.0.1
Revenue from Contract with Customer (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax $ 2,750,571 $ 3,311,822 $ 3,827,808
Contract with Customer, Asset, Net, Current 52,648 56,631  
Contract with Customer, Liability, Current (22,504) (30,133)  
Contract with Customer, Asset and Liability [Abstract]      
Contract with Customer, Asset, Net, Current 52,648 56,631  
Contract with Customer, Liability, Current (22,504) (30,133)  
Americas [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,215,613 1,662,643 1,806,672
Europe [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 747,024 831,811 1,216,810
Asia [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 787,934 817,368 804,326
Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,458,231 2,018,913 2,931,939
Diagnostics [Member] | Customer Concentration Risk [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax   330,700 638,600
Diagnostics [Member] | Americas [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 543,875 979,473 1,362,213
Diagnostics [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 438,457 534,343 982,476
Diagnostics [Member] | Asia [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 475,899 505,097 587,250
Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,292,340 1,292,909 895,869
Life Sciences [Member] | Americas [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 671,738 683,170 444,459
Life Sciences [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 308,567 297,468 234,334
Life Sciences [Member] | Asia [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 312,035 312,271 217,076
Life Sciences reagents [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 732,789 691,344 399,518
Life Sciences reagents [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0
Life Sciences reagents [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 732,789 691,344 399,518
Life Sciences instruments [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 381,262 405,554 329,584
Life Sciences instruments [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0
Life Sciences instruments [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 381,262 405,554 329,584
Life Sciences software [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 178,289 196,011 166,767
Life Sciences software [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0
Life Sciences software [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 178,289 196,011 166,767
Reproductive health [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 501,302 516,574 514,863
Reproductive health [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 501,302 516,574 514,863
Reproductive health [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0
Applied genomics [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 228,443 393,602 619,357
Applied genomics [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 228,443 393,602 619,357
Applied genomics [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0
Immunodiagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 728,486 1,108,737 1,797,719
Immunodiagnostics [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 728,486 1,108,737 1,797,719
Immunodiagnostics [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax $ 0 $ 0 $ 0
v3.24.0.1
Discontinued Operations Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Mar. 13, 2023
Aug. 01, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
(Benefit from) provision for income taxes on discontinued operations and dispositions $ 259,890,000 $ 17,101,000 $ 22,583,000    
Disposal Group, Including Discontinued Operation, Assets, Current 0 1,693,704,000      
Disposal Group, Including Discontinued Operation, Assets 0 1,693,704,000      
Disposal Group, Including Discontinued Operation, Liabilities, Current 0 272,865,000      
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents 0 14,999,000 14,999,000    
Analytical, Food and Enterprise Services businesses          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Depreciation, Discontinued Operations 0 8,011,000 12,897,000    
Amortization, Discontinued Operations 0 16,984,000 33,664,000    
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net   343,064,000      
(Loss) gain on disposition of discontinued operations before income taxes 811,472,000 0 0    
Disposal Group, Including Discontinued Operation, Consideration         $ 2,450,000,000
(Benefit from) provision for income taxes on discontinued operations and dispositions 259,890,000 17,101,000 22,583,000    
Disposal Group, Including Discontinued Operation, Inventory, Current   210,367,000      
Disposal Group, Including Discontinued Operation, Other Assets, Current   32,063,000      
Disposal Group, Including Discontinued Operation, Assets, Current   600,493,000      
Disposal Group, Including Discontinued Operation, Assets, Noncurrent   1,093,211,000      
Disposal Group, Including Discontinued Operation, Assets   1,693,704,000      
Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current   161,260,000      
Disposal Group, Including Discontinued Operation, Liabilities, Current   191,172,000      
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent   81,693,000      
Disposal Group, Including Discontinued Operation, Liabilities   272,865,000      
Capital Expenditure, Discontinued Operations $ 1,292,000 10,670,000 $ 13,868,000    
Disposal Group, Consideration, Receivable at Closing, Deferred Payments Tied to Transfer of the PKI Brand and Related Trademarks       $ 75,000,000  
Disposal Group, Consideration, Contingent on Exit Valuation       150,000,000  
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents   14,999,000      
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current   60,983,000      
Disposal Group, Including Discontinued Operation, Operating lease right-of-use assets, current   41,487,000      
Disposal Group, Including Discontinued Operation, Intangible Assets, Current   202,850,000      
Disposal Group, Including Discontinued Operation, Goodwill, Current   772,812,000      
Disposal Group, Including Discontinued Operation, Other assets, net, Current   15,079,000      
Disposal Group, Including Discontinued Operation, Accounts Payable   29,912,000      
Disposal Group, Including Discontinued Operation, Deferred taxes and long-term liabilities, Current   46,046,000      
Disposal Group, Including Discontinued Operation, Operating lease liabilities, Current   $ 35,647,000      
Disposal Group, Consideration, Receivable at Closing, Deferred Payments Tied to Transfer of the PKI Brand and Related Trademarks, Recognized at Closing       65,200,000  
Disposal Group, including Discontinued Operations, Fair Value of Consideration, Contingent on Exit Valuation       15,900,000  
Disposal Group, including Discontinued Operations, Receivable at Closing, Working Capital Adjustments       160,200,000  
Disposal Group, Consideration, Cash Proceeds at Closing       $ 2,130,000,000  
v3.24.0.1
Summary Operating Results of Discontinued Operations for the Periods Prior to Disposition (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Discontinued operations $ 259,890 $ 17,101 $ 22,583
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent 513,591 56,503 53,721
Analytical, Food and Enterprise Services businesses      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Disposal Group, Including Discontinued Operation, Revenue 176,324 1,298,376 1,239,361
Disposal Group, Including Discontinued Operation, Costs of Goods Sold 125,219 859,330 822,048
Disposal Group, Including Discontinued Operation, General and Administrative Expense 78,613 306,032 268,760
Disposal Group, Including Discontinued Operations, Research and development expenses 10,434 64,605 74,632
Disposal Group, Including Discontinued Operation, Operating Income (Loss) (37,942) 68,409 73,921
Income from discontinued operations before income taxes 773,481 73,604 76,304
(Loss) gain on disposition of discontinued operations before income taxes 811,472 0 0
Discontinued Operation, Other (Expense) Income, net (49) 5,195 2,383
Discontinued Operation, Total Other (Expense) Income 811,423 5,195 2,383
Discontinued operations 259,890 17,101 22,583
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent $ 513,591 $ 56,503 $ 53,721
v3.24.0.1
Restructuring and Contract Termination Charges, Net (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Restructuring Cost and Reserve [Line Items]      
Restructuring and other costs, net $ 26,601 $ (13,580) $ (14,358)
v3.24.0.1
Restructuring and Contract Termination Charges, Net Restructuring and Contract Termination Charges, Net (Schedule of Initial Charges) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Restructuring Cost and Reserve [Line Items]      
Restructuring and other costs, net $ 26,601 $ (13,580) $ (14,358)
v3.24.0.1
Restructuring and Contract Termination Charges, Net (Schedule of Restructuring Plan Activity) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Restructuring Reserve [Roll Forward]      
Restructuring and other costs, net $ 26,601 $ (13,580) $ (14,358)
v3.24.0.1
Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Income Tax Contingency [Line Items]      
Valuation Allowance, Amount $ 84,626 $ 96,681  
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Unrecognized tax benefits, beginning of period 57,948 61,658 $ 38,773
Gross increases - tax positions in prior period 64,697 1,489 2,877
Gross decreases - tax positions in prior period 0 (2,519) 0
Gross increases - current-period tax positions 14,969 7,187 149
Unrecognized Tax Benefits, Increase Resulting from Acquisition 0 0 22,697
Settlements 0 0 (2,252)
Lapse of statute of limitations (10,830) (8,625) (563)
Foreign currency translation adjustments 2,272 (1,242) (23)
Unrecognized tax benefits, end of period   57,948 61,658
Income Tax Penalties and Interest Accrued 6,300 7,200  
Income Tax Penalties and Interest Expense (1,100) (500) 1,800
Unrecognized Tax Benefits, Ending Balance 129,056 57,948 61,658
Unrecognized Tax Benefits Expected To Be Resolved With In A Year 71,600    
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount (4,737) $ (4,940) $ 37,147
General Business [Member]      
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Tax Credit Carryforward, Amount 100    
State and Local Jurisdiction [Member]      
Income Tax Contingency [Line Items]      
Operating Loss Carryforwards 8,900    
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Tax Credit Carryforward, Amount 13,800    
Foreign Tax Authority [Member]      
Income Tax Contingency [Line Items]      
Operating Loss Carryforwards 439,800    
Internal Revenue Service (IRS) [Member]      
Income Tax Contingency [Line Items]      
Operating Loss Carryforwards $ 109,800    
v3.24.0.1
Income Taxes Income Before Income taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Income Tax Contingency [Line Items]      
U.S. $ 51,314 $ 326,438 $ 547,705
Non-U.S. 131,662 325,399 655,877
Income from continuing operations before income taxes $ 182,976 $ 651,837 $ 1,203,582
v3.24.0.1
Income Taxes Components of the Provision (Benefits from) Income Tax (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Income Tax Contingency [Line Items]      
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount $ (18,479) $ (5,221) $ (33,847)
Federal current 39,800 115,436 154,905
Federal deferred expense (benefit) (60,845) (45,246) (37,858)
Federal total (21,045) 70,190 117,047
State current 9,183 27,757 53,961
State deferred expense (benefit) (19,619) (16,139) 3,602
State total (10,436) 11,618 57,563
Non-U.S. current 78,154 101,891 160,608
Non-U.S.deferred expense benefit (43,200) (44,538) (21,072)
Non-U.S. total 34,954 57,353 139,536
Total current 127,137 245,084 369,474
Total deferred expense (benefit) (123,664) (105,923) (55,328)
Total 3,473 139,161 314,146
Discontinued operations 259,890 17,101 22,583
Total provision for income taxes $ 263,363 $ 156,262 $ 336,729
v3.24.0.1
Income Taxes Reconciliation of Income Tax Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Income Tax Contingency [Line Items]      
Tax at statutory rate $ 38,346 $ 136,886 $ 252,752
Non-U.S. rate differential, net (18,479) (5,221) (33,847)
U.S. taxation of multinational operations (4,594) 22,102 7,964
State income taxes, net (265) 7,820 36,832
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount (12,795) 0 14,031
Prior year tax matters 3,971 (10,160) 1,850
Effect of Stock Compensation 2,225 845 (2,187)
Federal tax credits (4,718) (7,132) (2,715)
Effective Income Tax Rate Reconciliation, Transfer Pricing Matters, Amount (6,725) 0 0
Change in valuation allowance 6,772 4,964 (179)
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount (4,737) (4,940) 37,147
Other, net 4,472 (6,003) 2,498
Total $ 3,473 $ 139,161 $ 314,146
v3.24.0.1
Income Taxes Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Income Tax Contingency [Line Items]    
Inventory $ 12,934 $ 17,920
Reserves and accruals 63,711 70,912
Accrued compensation 18,339 23,868
Net operating loss and credit carryforwards 133,919 117,953
Accrued pension 11,089 11,653
Restructuring reserve 1,588 1,640
Deferred revenue 17,539 22,644
Capitalized research and development expenses 47,188 44,922
Deferred Tax Assets, Unrealized Foreign Exchange Losses 12,502 11,158
Deferred tax assets, operating lease liabilities 29,319 43,547
All other, net 1,610 841
Deferred Tax Assets, Gross 349,738 367,058
Postretirement health benefits (4,452) (4,379)
Depreciation and amortization (784,925) (916,581)
Deferred Tax Liabilities, Prepaid Expenses (349) (3,515)
Deferred tax liability on foreign earnings 17,587 (15,782)
Deferred tax liabilities, operating lease right-of-use assets (26,301) 39,281
Total deferred tax liabilities (833,614) (979,538)
Valuation allowance (84,626) (96,681)
Deferred Tax Liabilities, Net $ (568,502) $ (709,161)
v3.24.0.1
Income Taxes Summary of Loss and Tax Credit Carryforwards (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Income Tax Contingency [Line Items]    
Valuation Allowance, Amount $ 84,626 $ 96,681
State and Local Jurisdiction [Member]    
Income Tax Contingency [Line Items]    
Operating Loss Carryforwards 8,900  
Tax Credit Carryforward, Amount 13,800  
Foreign Tax Authority [Member]    
Income Tax Contingency [Line Items]    
Operating Loss Carryforwards 439,800  
Internal Revenue Service (IRS) [Member]    
Income Tax Contingency [Line Items]    
Operating Loss Carryforwards 109,800  
General Business [Member]    
Income Tax Contingency [Line Items]    
Tax Credit Carryforward, Amount $ 100  
v3.24.0.1
Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Earnings Per Share [Abstract]      
Number of common shares-basic 124,704 126,155 116,165
Effect of dilutive securities, Stock options 108 249 391
Effect of dilutive securities, Restricted stock 0 22 118
Number of common shares-diluted 124,812 126,426 116,674
Number of potentially dilutive securities excluded from calculation due to antidilutive impact 1,089 611 487
v3.24.0.1
Accounts Receivable, Net (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]      
Accounts receivable, net $ 632,811 $ 612,780  
Accounts Receivable, after Allowance for Credit Loss, Noncurrent 29,593 34,040  
Accounts Receivable, after Allowance for Credit Loss 662,404 646,820  
Accounts Receivable, Allowance for Credit Loss [Roll Forward]      
Accounts Receivable, Allowance for Credit Loss, Beginning Balance 37,543 38,254 $ 33,497
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 9,067 9,857 6,854
Accounts Receivable, Allowance for Credit Loss, Writeoff (3,559) (9,672) (2,198)
Accounts Receivable, Allowance for Credit Loss, Ending Balance 43,380 37,543 38,254
Allowance for Credit Loss [Abstract]      
Allowance for Credit Loss, Receivables, Other Period Activity $ 329 $ (896) $ 101
v3.24.0.1
Inventories, Net (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 197,268 $ 190,640
Work in progress 69,176 68,206
Finished goods 161,618 146,616
Total inventories $ 428,062 $ 405,462
v3.24.0.1
Property, Plant and Equipment, Net (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross $ 983,139 $ 857,143  
Accumulated depreciation (473,485) (374,193)  
Total property, plant and equipment, net 509,654 482,950  
Depreciation expense 66,700 56,400 $ 54,900
Land [Member]      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 29,635 28,340  
Building and leasehold Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 358,380 346,164  
Machinery and Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross $ 595,124 $ 482,639  
v3.24.0.1
Investments, Debt and Equity Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Equity Securities without Readily Determinable Fair Value [Line Items]    
Marketable Securities, Noncurrent $ 13,913 $ 11,083
Equity Securities without Readily Determinable Fair Value, Amount 57,206 54,503
Equity investments, carried at cost minus impairment, if any 47,260 50,654
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount 31,300 30,700
Equity Securities, FV-NI and without Readily Determinable Fair Value 9,946 3,849
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount 5,000  
Marketable securities - held to maturity (current) 689,916 $ 0
Investments in debt securities, Notional Amount, Due Within One to Five Years $ 19,800  
v3.24.0.1
Marketable Securities and Investments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Debt Securities, Available-for-sale [Line Items]      
Marketable Securities, Noncurrent $ 13,913 $ 11,083  
Marketable securities - held to maturity (current) 689,916 0  
Unrealized (losses) gains on securities, net of tax (181) 5 $ 237
Marketable Securities and Investments 773,315 108,086  
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount 5,000    
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount 31,300 30,700  
Investments in debt securities 12,280 $ 42,500  
Investments in debt securities, Notional Amount, Due Within One to Five Years 19,800    
Investments in debt securities, Convertible to Equity Securities or are due and payable upon event of default 12,300    
Investments in debt securities, Convertible to Equity Securities or are due and payable upon event of default, Notional Amount 25,000    
Other than temporary impairment, included in Interest and other expense, net $ 34,500    
v3.24.0.1
Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Goodwill and Intangible Assets Net [Line Items]      
Total amortization expense related to finite-lived intangible assets $ 365,100 $ 370,600 $ 256,600
Future Amortization Expense, Year One 362,600    
Future Amortization Expense, Year Two 335,000    
Future Amortization Expense, Year Three 328,800    
Future Amortization Expense, Year Four 301,600    
Future Amortization Expense, Year Five 275,900    
Finite-Lived Intangible Assets, Net 3,022,321 3,377,174  
Beginning balance $ 6,533,550 6,481,768 6,627,119
Impairment Testing Date January 2, 2023    
Trade Names And Trademarks [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Finite-Lived Intangible Assets, Net $ 71,761 85,863  
Licenses [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Finite-Lived Intangible Assets, Net 10,467 8,360  
Diagnostics [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Beginning balance $ 1,945,612 $ 1,930,193 $ 1,970,350
v3.24.0.1
Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Changes in the carrying amount of goodwill    
Goodwill, Beginning Balance $ 6,481,768 $ 6,627,119
Foreign currency translation 51,782 (139,885)
Acquisitions, earn outs and other   (5,466)
Ending balance 6,533,550 6,481,768
Life Sciences [Member]    
Changes in the carrying amount of goodwill    
Goodwill, Beginning Balance 4,551,575 4,656,769
Foreign currency translation 36,363 (98,268)
Acquisitions, earn outs and other   (6,926)
Ending balance 4,587,938 4,551,575
Diagnostics [Member]    
Changes in the carrying amount of goodwill    
Goodwill, Beginning Balance 1,930,193 1,970,350
Foreign currency translation 15,419 (41,617)
Acquisitions, earn outs and other   1,460
Ending balance $ 1,945,612 $ 1,930,193
v3.24.0.1
Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Net amortizable intangible assets $ 3,022,321 $ 3,377,174
Intangible Assets, Net (Excluding Goodwill) 3,022,321 3,377,174
Patents [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 27,811 28,020
Less: Accumulated amortization (26,072) (26,055)
Net amortizable intangible assets 1,739 1,965
Trade Names And Trademarks [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 145,542 149,453
Less: Accumulated amortization (73,781) (63,590)
Net amortizable intangible assets 71,761 85,863
Licenses [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 27,018 62,614
Less: Accumulated amortization (16,551) (54,254)
Net amortizable intangible assets 10,467 8,360
Core Technology [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 1,582,458 1,556,740
Less: Accumulated amortization (607,814) (449,689)
Net amortizable intangible assets 974,644 1,107,051
Customer Relationships [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 2,842,531 2,943,761
Less: Accumulated amortization (878,821) (775,104)
Net amortizable intangible assets 1,963,710 2,168,657
In Process Research and Development [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets $ 0 $ 5,278
v3.24.0.1
Debt (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Aug. 24, 2021
Unamortized discount and debt issuance costs $ (27,563)    
Unamortized Debt Issuance Expense 22,715 $ 28,820  
Maturities of Long-term Debt [Abstract]      
2024 723,291    
2025 206    
2026 553,570    
2027 92    
2028 500,046    
2029 and Thereafter 2,150,000    
Long-term Debt Before Unamortized Discount 3,927,205    
Total (3,899,642)    
Other Long-term Debt, Current 721,872 470,929  
Debt Instrument, Unamortized Discount 4,848 6,020  
Long-term Debt, Gross 3,203,914 3,957,257  
Debt, Long-term and Short-term, Combined Amount 3,927,205 4,429,116  
Current Portion of Long-Term Debt, Gross 723,291 471,859  
Current portion of long-term debt 721,872 470,929  
Fair Value, Inputs, Level 2 [Member]      
Maturities of Long-term Debt [Abstract]      
Total (3,177,770) (3,923,347)  
Debt, Long-term and Short-term, Combined Amount 3,899,642 4,394,276  
Fair Value, Inputs, Level 1 [Member]      
Maturities of Long-term Debt [Abstract]      
Carrying value of Investments in US Treasury Securities measured at amortized cost (held-to-maturity) 689,900    
Long-term Debt      
Unamortized Debt Issuance Expense 21,414 27,953  
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Unamortized Discount 4,730 5,957  
Long-term Debt - Current Portion [Member]      
Unamortized Debt Issuance Expense 1,301 867  
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Unamortized Discount 118 63  
Line of Credit, Maturing September 17, 2024 [Member]      
Aggregate borrowings under the amended facility   0  
Unamortized Debt Issuance Expense   2,641  
Maturities of Long-term Debt [Abstract]      
Total   (2,641)  
Debt Instrument, Unamortized Discount   0  
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]      
Unamortized Debt Issuance Expense 4,781 5,537  
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Unamortized Discount 1,727 2,000  
Long-term Debt, Gross 850,000 850,000  
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Fair Value, Inputs, Level 2 [Member]      
Maturities of Long-term Debt [Abstract]      
Total (843,492) (842,463)  
1.875 Percent Ten Year Senior Unsecured Notes [Member]      
Unamortized Debt Issuance Expense 1,279 1,779  
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Unamortized Discount 1,438 1,902  
Long-term Debt, Gross 553,450 533,950  
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Fair Value, Inputs, Level 2 [Member]      
Maturities of Long-term Debt [Abstract]      
Total (550,733) (530,269)  
Line of Credit, Maturing August 24, 2026      
Unsecured revolving credit facility, amount     $ 1,500,000
Line of Credit Facility, Remaining Borrowing Capacity 1,490,000    
Letters of credit issued and outstanding 7,100    
Aggregate borrowings under the amended facility 0    
Unamortized Debt Issuance Expense 1,966    
Maturities of Long-term Debt [Abstract]      
Total (1,966)    
Debt Instrument, Unamortized Discount $ 0    
Line of Credit, Maturing August 24, 2026 | Unsecured Revolving Credit Facility [Member] | Base Rate Option Two [Member]      
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Basis Spread on Variable Rate 0.50%    
Line of Credit, Maturing August 24, 2026 | Unsecured Revolving Credit Facility [Member] | Base Rate Option Three [Member]      
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Basis Spread on Variable Rate 1.00%    
0.550% Senior Unsecured Notes due 2023      
Unamortized Debt Issuance Expense   867  
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Unamortized Discount   63  
Current portion of long-term debt   467,138  
Repayments of Long-Term Debt $ 467,100    
0.550% Senior Unsecured Notes due 2023 | Fair Value, Inputs, Level 2 [Member]      
Maturities of Long-term Debt [Abstract]      
Current portion of long-term debt   466,208  
0.850% Senior Unsecured Notes due 2024      
Unamortized Debt Issuance Expense 1,301 3,136  
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Unamortized Discount 118 283  
Long-term Debt, Gross   771,659  
Current portion of long-term debt 711,479    
Debt Instrument, Repurchase Amount 60,200    
0.850% Senior Unsecured Notes due 2024 | Fair Value, Inputs, Level 2 [Member]      
Maturities of Long-term Debt [Abstract]      
Total   (768,240)  
Current portion of long-term debt 710,060    
1.900% Senior Unsecured Notes due 2028      
Unamortized Debt Issuance Expense 3,024 3,631  
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Unamortized Discount 250 301  
Long-term Debt, Gross 500,000 500,000  
1.900% Senior Unsecured Notes due 2028 | Fair Value, Inputs, Level 2 [Member]      
Maturities of Long-term Debt [Abstract]      
Total (496,726) (496,068)  
2.55 Percent Senior Unsecured Notes due in 2031      
Unamortized Debt Issuance Expense 2,638 2,978  
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Unamortized Discount 101 114  
Long-term Debt, Gross 400,000 400,000  
2.55 Percent Senior Unsecured Notes due in 2031 | Fair Value, Inputs, Level 2 [Member]      
Maturities of Long-term Debt [Abstract]      
Total (397,261) (396,908)  
2.250% Senior Unsecured Notes due in 2031      
Unamortized Debt Issuance Expense 3,568 3,991  
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Unamortized Discount 1,210 1,353  
Long-term Debt, Gross 500,000 500,000  
2.250% Senior Unsecured Notes due in 2031 | Fair Value, Inputs, Level 2 [Member]      
Maturities of Long-term Debt [Abstract]      
Total (495,222) (494,656)  
3.625 Percent Senior Unsecured Notes due in 2051      
Unamortized Debt Issuance Expense 4,158 4,260  
Maturities of Long-term Debt [Abstract]      
Debt Instrument, Unamortized Discount 4 4  
Long-term Debt, Gross 400,000 400,000  
3.625 Percent Senior Unsecured Notes due in 2051 | Fair Value, Inputs, Level 2 [Member]      
Maturities of Long-term Debt [Abstract]      
Total (395,838) (395,736)  
Other Debt Facilities - Non-current      
Unamortized Debt Issuance Expense 0 0  
Maturities of Long-term Debt [Abstract]      
Other Long-term Debt, Noncurrent 464 1,648  
Debt Instrument, Unamortized Discount 0 0  
Other Debt Facilities - Non-current | Fair Value, Inputs, Level 2 [Member]      
Maturities of Long-term Debt [Abstract]      
Other Long-term Debt, Noncurrent 464 1,648  
Other Debt Facilities - Current      
Unamortized Debt Issuance Expense 0 0  
Maturities of Long-term Debt [Abstract]      
Other Long-term Debt, Current 11,812    
Debt Instrument, Unamortized Discount 0 0  
Current portion of long-term debt   4,721  
Other Debt Facilities - Current | Fair Value, Inputs, Level 2 [Member]      
Maturities of Long-term Debt [Abstract]      
Other Long-term Debt, Current $ 11,812    
Current portion of long-term debt   $ 4,721  
v3.24.0.1
Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]    
Payroll and incentives $ 50,526 $ 52,331
Employee benefits 43,279 51,983
Deferred revenue 135,555 135,531
Federal, non-U.S. and state income taxes 88,159 45,625
Operating Lease liabilities, Accrued, Current 32,906 31,217
Contract with Customer, Liability, Current 22,504 30,133
Other accrued operating expenses 174,045 211,176
Accrued expenses and other current liabilities $ 524,470 $ 527,863
v3.24.0.1
Employee Benefit Plans (Schedule of Net Benefit Costs, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 5,736 $ 6,331 $ 5,174
Interest cost 19,585 10,751 9,440
Expected return on plan assets (14,600) (22,056) (24,417)
Actuarial loss (gain) 9,341 (23,706) (19,514)
Net periodic benefit cost $ 20,062 $ (28,680) $ (29,317)
v3.24.0.1
Employee Benefit Plans (Schedule of Net Funded Status, Pension Plans) (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Actuarial assumptions as of the year-end measurement date:          
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Projected Benefit Obligation   $ 134,409 $ 120,283    
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets   0 0    
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation   134,814 120,736    
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets   0 $ 0    
UNITED STATES | Subsequent Event [Member]          
Change in plan assets:          
Employer's contributions $ 10,000        
Other Pension Plan [Member]          
Actuarial assumptions as of the year-end measurement date:          
Rate of compensation increase     3.16%    
Other Postretirement Benefit Plans, Defined Benefit [Member]          
Net amounts recognized in the consolidated balance sheets consist of:          
Net amounts recognized in the consolidated balance sheets   (18,500) $ (17,100)    
Foreign Plan [Member]          
Actuarial present value of benefit obligations: [Abstract]          
Accumulated benefit obligations   227,174 207,503    
Change in benefit obligations:          
Projected benefit obligations at beginning of year 227,579 207,955 339,390    
Service cost   4,011 4,956    
Interest cost   8,843 3,671    
Benefit obligation classified in discontinued operations   0 8,261    
Benefit obligation classified in discontinued operations   0 (8,261)    
Actuarial loss (gain)   12,871 (88,724)    
Effect of exchange rate changes   8,960 (28,099)    
Projected benefit obligations at end of year   227,579 207,955 $ 339,390  
Change in plan assets:          
Fair value of plan assets at beginning of year 112,305 106,741 181,189    
Actual return on plan assets   7,094 (46,383)    
Benefits paid and plan expenses   (15,061) (14,978)    
Employer's contributions   7,606 6,572    
Effect of exchange rate changes   5,925 (19,659)    
Fair value of plan assets at end of year   112,305 106,741 $ 181,189  
Net amounts recognized in the consolidated balance sheets consist of:          
Net amounts recognized in the consolidated balance sheets   (115,274) (101,214)    
Assets for Plan Benefits, Defined Benefit Plan   19,540 19,521    
Current liabilities   (6,899) (6,568)    
Noncurrent liabilities   $ (127,915) $ (114,167)    
Actuarial assumptions as of the year-end measurement date:          
Discount rate   3.69% 4.12% 1.41% 0.92%
Rate of compensation increase   3.19% 3.16% 2.78% 2.78%
Expected rate of return on assets     3.92% 1.11% 2.10%
Defined Benefit Plan, Benefit Obligation, Benefits Paid   $ 15,061 $ 14,978    
UNITED STATES          
Actuarial present value of benefit obligations: [Abstract]          
Accumulated benefit obligations   208,505 231,492    
Change in benefit obligations:          
Projected benefit obligations at beginning of year 208,505 231,492 299,826    
Service cost   1,725 1,375    
Interest cost   10,742 7,080    
Benefit obligation classified in discontinued operations   0 0    
Benefit obligation classified in discontinued operations   0 0    
Actuarial loss (gain)   4,441 (56,919)    
Effect of exchange rate changes   0 0    
Projected benefit obligations at end of year   208,505 231,492 $ 299,826  
Change in plan assets:          
Fair value of plan assets at beginning of year $ 202,331 216,748 290,116    
Actual return on plan assets   15,478 (53,498)    
Benefits paid and plan expenses   (39,895) (19,870)    
Employer's contributions   10,000 0    
Effect of exchange rate changes   0 0    
Fair value of plan assets at end of year   202,331 216,748 $ 290,116  
Net amounts recognized in the consolidated balance sheets consist of:          
Net amounts recognized in the consolidated balance sheets   (6,174) (14,744)    
Assets for Plan Benefits, Defined Benefit Plan   0 0    
Current liabilities   0 0    
Noncurrent liabilities   $ (6,174) $ (14,744)    
Actuarial assumptions as of the year-end measurement date:          
Discount rate   4.54% 4.84% 2.44% 2.21%
Rate of compensation increase   0.00% 0.00% 0.00% 0.00%
Expected rate of return on assets     4.80% 7.25% 7.25%
Defined Benefit Plan, Benefit Obligation, Benefits Paid   $ 39,895 $ 19,870    
v3.24.0.1
Employee Benefit Plans (Schedule of Allocation of Plan Assets, Pension Plans) (Details)
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Equity Securities   100.00% 100.00%
UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Equity Securities   100.00% 100.00%
Other Securities [Member] | Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Equity Securities   100.00% 100.00%
Other Securities [Member] | UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Equity Securities   0.00% 0.00%
Debt Securities [Member] | Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Equity Securities   0.00% 0.00%
Debt Securities [Member] | UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Equity Securities   94.00% 56.00%
Equity Securities [Member] | Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Equity Securities   0.00% 0.00%
Equity Securities [Member] | UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Equity Securities   6.00% 44.00%
Forecast [Member] | Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Equity Securities 100.00%    
Forecast [Member] | UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Equity Securities 100.00%    
Forecast [Member] | Minimum [Member] | Equity Securities [Member] | Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 0.00%    
Forecast [Member] | Minimum [Member] | Equity Securities [Member] | UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 40.00%    
Forecast [Member] | Minimum [Member] | Debt Securities [Member] | Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 0.00%    
Forecast [Member] | Minimum [Member] | Debt Securities [Member] | UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 40.00%    
Forecast [Member] | Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 95.00%    
Forecast [Member] | Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 0.00%    
Forecast [Member] | Maximum [Member] | Equity Securities [Member] | Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 5.00%    
Forecast [Member] | Maximum [Member] | Equity Securities [Member] | UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 60.00%    
Forecast [Member] | Maximum [Member] | Debt Securities [Member] | Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 5.00%    
Forecast [Member] | Maximum [Member] | Debt Securities [Member] | UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 60.00%    
Forecast [Member] | Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 100.00%    
Forecast [Member] | Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit, Target Asset Allocation Percentage 10.00%    
v3.24.0.1
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 314,636 $ 323,489  
Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 14,223 14,483  
Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7,011 61,680  
Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,350 20,148  
Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,068 9,902  
Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 189,318 105,126  
Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   17,088  
Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 100,666 95,062  
Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 89,880 142,559  
Fair Value, Inputs, Level 1 [Member] | Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 14,223 14,483  
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7,011 61,680  
Fair Value, Inputs, Level 1 [Member] | Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,350 20,148  
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,068 9,902  
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 65,228 36,346  
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Fair Value, Inputs, Level 1 [Member] | Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 124,090 85,868  
Fair Value, Inputs, Level 2 [Member] | Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 124,090 68,780  
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   17,088  
Fair Value, Inputs, Level 2 [Member] | Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 100,666 95,062  
Fair Value, Inputs, Level 3 [Member] | Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Fair Value, Inputs, Level 3 [Member] | Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 100,666 $ 95,062 $ 165,680
v3.24.0.1
Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 03, 2021
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year $ 323,489    
Fair value of plan assets at end of year 314,636 $ 323,489  
Foreign liability driven investment [Member]      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 95,062    
Fair value of plan assets at end of year 100,666 95,062  
Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 9,902    
Fair value of plan assets at end of year 1,068 9,902  
Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 95,062    
Fair value of plan assets at end of year 100,666 95,062  
Fair Value, Inputs, Level 3 [Member] | Foreign liability driven investment [Member]      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 95,062 165,680  
Defined Benefit Plan, Realized losses   (18,411)  
Fair value of plan assets at end of year 100,666 95,062  
Defined Benefit Plan, Unrealized Gains     $ (45,568)
Defined Benefit Plan, Realized Gains   (6,639)  
Defined Benefit Plan, Foreign exchange losses 5,957    
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held 5,698    
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Pension Benefits Paid (6,051)    
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 0    
Fair value of plan assets at end of year $ 0 $ 0  
v3.24.0.1
Employee Benefit Plans (Schedule of Expected Benefit Payments, Pension Plans) (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
2018   $ 12,331
2019   12,598
2020   12,720
2021   12,673
2022   12,914
2023-2026   64,702
Foreign Plan [Member] | Forecast [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Expected contributions in next fiscal year $ 6,900  
UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
2018   18,882
2019   18,583
2020   18,240
2021   17,864
2022   17,408
2023-2026   $ 77,782
v3.24.0.1
Employee Benefit Plans (Schedule of Net Benefit Costs, Other Postretirement Benefits) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 5,736 $ 6,331 $ 5,174
Interest cost 19,585 10,751 9,440
Expected return on plan assets (14,600) (22,056) (24,417)
Actuarial loss (gain) (9,341) 23,706 19,514
Net periodic benefit cost $ 20,062 $ (28,680) $ (29,317)
v3.24.0.1
Employee Benefit Plans (Schedule of Net Funded Status, Other Postretirement Benefit Plans) (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Other Postretirement Benefit Plans, Defined Benefit [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Net amounts recognized in the consolidated balance sheets $ (18,500) $ (17,100)
v3.24.0.1
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Other Postretirement Benefit Plans) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 314,636 $ 323,489  
Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 89,880 142,559  
Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 124,090 85,868  
Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 100,666 95,062  
Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 14,223 14,483  
Cash [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 14,223 14,483  
Cash [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Cash [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7,011 61,680  
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7,011 61,680  
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,350 20,148  
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,350 20,148  
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 189,318 105,126  
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 65,228 36,346  
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 124,090 68,780  
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   17,088  
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   17,088  
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 100,666 95,062  
Foreign liability driven investment [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign liability driven investment [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign liability driven investment [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 100,666 95,062 $ 165,680
Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,068 9,902  
Equity Securities, Emerging Markets Growth [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,068 9,902  
Equity Securities, Emerging Markets Growth [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, Emerging Markets Growth [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 0 $ 0  
v3.24.0.1
Employee Benefit Plans (Schedule of Expected Benefit Payments, Other Postretirement Benefits) (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
2018   $ 12,331
2019   12,598
2020   12,720
2021   12,673
2022   12,914
2023-2026   64,702
UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
2018   18,882
2019   18,583
2020   18,240
2021   17,864
2022   17,408
2023-2026   $ 77,782
Forecast [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year $ 6,900  
v3.24.0.1
Employee Benefit Plans (Savings Plan) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation 100.00%    
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match 5.00%    
Defined Benefit, 401(k) Savings Plan Expense $ 15.0 $ 20.0 $ 16.5
v3.24.0.1
Employee Benefit Plans (Supplemental Executive Retirement Plan) (Details) - Supplemental Employee Retirement Plans, Defined Benefit [Member] - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Defined Benefit Plan Disclosure [Line Items]      
Projected benefit obligation $ 18.6 $ 18.9  
Fair value of plan assets 0.6 0.9  
Pension expense $ 1.5 $ (3.2) $ 0.2
v3.24.0.1
Contingencies (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
years
Jan. 01, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]    
Management's estimate of total cost of ultimate disposition of known environmental matters | $ $ 14.1 $ 12.2
Number of years over which estimated environmental cost will be paid | years 10  
v3.24.0.1
Stock Plans (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total income tax benefit recognized for stock-based compensation $ 10,600 $ 12,800 $ 12,200
Aggregate intrinsic value for stock options outstanding $ 9,400    
Weighted average remaining contractual term of options (in years) 4 years 1 month 6 days    
Aggregate intrinsic value for stock options exercisable $ 9,300    
Weighted average remaining contractual term of options exercisable (in years) 3 years 4 months 24 days    
Number of shares vested and expected to vest in the future 1,100,000    
Aggregate intrinsic value of vested and expected to vest stock options $ 9,400    
Weighted average remaining contractual term for options vested and expected to vest 4 years 1 month 6 days    
Total pre-tax stock-based compensation expense $ 41,410 51,518 29,675
Restricted Stock Awards [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted-average grant-date fair value of stock granted (per share) $ 128.79    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 30,000    
Fair value of restricted stock awards vested $ 31,500 32,800 11,600
Total pre-tax stock-based compensation expense 28,300 $ 34,200 $ 16,300
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted $ 27,100    
Shares/units granted 139,000    
Awards/units outstanding 341,000 453,000  
Weighted-average period for recognition of unrecognized compensation cost, years 1 year 6 months    
Option vesting period (in years) 3 years    
Employee Stock Purchase Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares authorized under plan 5,000,000    
Weighted-average grant-date fair value of stock granted (per share) $ 108.37 $ 134.05 $ 168.11
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date 95.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate 10.00%    
Shares/units granted 28,899 30,818 21,578
Shares available for grant under employee stock purchase plan 700,000    
Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted-average grant-date fair value of options $ 45.18 $ 48.09 $ 40.00
Total intrinsic value of options exercised $ 2,400 $ 13,900 $ 32,400
Cash received from option exercises 4,300 14,100 25,100
Total pre-tax stock-based compensation expense 9,100 $ 9,500 $ 5,600
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted $ 11,200    
Weighted-average period for recognition of unrecognized compensation cost, years 1 year 7 months 6 days    
Option vesting period (in years) 3 years    
Stock Options Expiration Period After Date of Grant 7 years    
2019 Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares authorized under plan     6,250,000
v3.24.0.1
Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 41,410 $ 51,518 $ 29,675
Cost of sales [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 4,224 7,459 3,193
Research and development expenses [Member ]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 5,276 6,799 2,393
Selling, general and administrative and other expenses [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 31,910 $ 37,260 $ 24,089
v3.24.0.1
Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Share-Based Payment Arrangement [Abstract]      
Risk-free interest rate 4.10% 2.30% 0.90%
Expected dividend yield 0.20% 0.20% 0.20%
Expected lives, years 5 years 5 years 5 years
Expected stock volatility 32.70% 28.50% 27.30%
v3.24.0.1
Stock Plans (Summary of Stock Option Activity) (Details)
shares in Thousands
 12 Months Ended
Dec. 31, 2023
$ / shares
shares
Stock option activity  
Shares outstanding at beginning of the year 1,048
Shares granted 168
Shares exercised (58)
Shares canceled (49)
Shares forfeited (36)
Shares outstanding at end of year 1,073
Shares exercisable at end of year 693
Number of shares vested and expected to vest in the future 1,100
Weighted-average price, outstanding at beginning of year (per share) | $ / shares $ 132.32
Weighted-average price, granted (per share) | $ / shares 128.35
Weighted-average price, exercised (per share) | $ / shares 76.12
Weighted-average price, canceled (per share) | $ / shares 154.37
Weighted-average price, forfeited (per share) | $ / shares 146.13
Weighted-average price, outstanding at end of year (per share) | $ / shares 133.28
Weighted-average price, exercisable at end of year (per share) | $ / shares $ 125.06
v3.24.0.1
Stock Plans (Summary of Restricted Stock Award Activity) (Details) - Restricted Stock Awards [Member]
shares in Thousands
 12 Months Ended
Dec. 31, 2023
$ / shares
shares
Restricted stock award activity  
Nonvested at beginning of year | shares 453
Shares, granted | shares 139
Shares, vested | shares (221)
Shares, forfeited | shares (30)
Nonvested at end of year | shares 341
Weighted-average grant-date fair value, nonvested at beginning of year (per share) | $ / shares $ 152.79
Weighted-average grant-date fair value of stock granted (per share) | $ / shares 128.79
Weighted-average grant-date fair value, vested (per share) | $ / shares 142.69
Weighted-average grant-date fair value, forfeited (per share) | $ / shares 147.80
Weighted-average grant-date fair value, nonvested at end of year (per share) | $ / shares $ 149.98
v3.24.0.1
Stockholders' Equity (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Oct. 01, 2023
Jul. 02, 2023
Apr. 02, 2023
Jan. 01, 2023
Oct. 02, 2022
Jul. 03, 2022
Apr. 03, 2022
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Apr. 27, 2023
Jul. 22, 2022
Schedule of Stockholders' Equity [Line Items]                            
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans                   103,144 115,247 71,248    
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans                   $ 13,100 $ 18,100 $ 10,500    
Cash dividends (per share)   $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28        
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations                   $ 392,302 80,638 73,072    
Dividends accrued   $ 8,600               8,600        
Unrecognized prior service credit (cost), net of tax                   $ 0 $ 44 $ (95)    
Repurchase Program, 07/22/2022                            
Schedule of Stockholders' Equity [Line Items]                            
Number of common stock repurchased in open market                   1,004,544        
Stock Repurchase Program, Authorized Amount                           $ 300,000
Aggregate Cost of Repurchased Common Shares Under Repurchase Program                   $ 131,300        
Repurchase Program, 04/27/2023                            
Schedule of Stockholders' Equity [Line Items]                            
Number of common stock repurchased in open market                   2,159,985        
Stock Repurchase Program, Remaining Authorized Repurchase Amount   $ 355,400               $ 355,400        
Stock Repurchase Program, Authorized Amount                         $ 600,000  
Aggregate Cost of Repurchased Common Shares Under Repurchase Program                   $ 244,600        
Subsequent Event [Member]                            
Schedule of Stockholders' Equity [Line Items]                            
Cash dividends (per share) $ 0.07                          
Dividends Payable, Date Declared Jan. 25, 2024                          
v3.24.0.1
Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Cumulative Translation Adjustment Summary [Roll Forward]        
Foreign currency translation adjustment, net of tax, beginning of year $ (446,664) $ (161,810) $ (30,937)  
Current year change 80,172 (284,854) (130,873)  
Foreign currency translation adjustment, net of tax, end of year (275,678) (446,664) (161,810)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 90,814      
Foreign currency translation adjustment, net of tax, Reclassification to Retained Earnings 90,814      
Unrecognized prior service costs, net of tax, reclassification to retained earnings 0      
Unrealized (losses) gains on securities, net of tax, reclassification to retained earnings 0      
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax 170,805 (284,805) (130,731)  
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 79,991 (284,805) (130,731)  
Unrecognized prior service costs, net of tax (798) (798) (842) $ (747)
Unrecognized prior service costs, net of tax, current year change 0 44 (95)  
Unrealized (losses) gains on securities, net of tax (216) (35) (40) (277)
Unrealized (losses) gains on securities, net of tax, current year change (181) 5 237  
Accumulated other comprehensive income (loss) $ (276,692) $ (447,497) $ (162,692) $ (31,961)
v3.24.0.1
Derivatives And Hedging Activities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Derivative [Line Items]      
Company's business conducted outside United States 60.00%    
Payments for (Proceeds from) Hedge, Financing Activities $ 0 $ 762 $ 4,482
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months $ 0    
European And Asian Currencies [Member]      
Derivative [Line Items]      
Maximum maturity period for foreign exchange contracts, in months 12 months    
Duration of foreign currency derivative contract, days 30 days    
Fair Value Hedging [Member]      
Derivative [Line Items]      
Derivative, Notional Amount $ 412,100 476,900  
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Derivative [Line Items]      
Foreign Currency Contract, Asset, Fair Value Disclosure (1,697) (2,142)  
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Net Investment Hedging [Member]      
Derivative [Line Items]      
Notional Amount of Nonderivative Instruments 498,600    
Unrealized Gain (Loss) on Net Investment Hedge in AOCI $ (19,500) $ 34,500 $ 33,200
v3.24.0.1
Fair Value Measurements (Narrative) (Details)
$ in Thousands, € in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
Jan. 01, 2023
USD ($)
Jan. 02, 2022
USD ($)
Dec. 31, 2023
EUR (€)
Jan. 01, 2023
EUR (€)
Jan. 03, 2021
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 40,005 $ 46,618 $ 57,996     $ 2,953
Long-term Debt 3,899,642          
Discount on senior unsecured notes (4,848) (6,020)        
Unamortized Debt Issuance Expense $ 22,715 28,820        
Business Combination, Contingent Consideration Arrangements, Maximum Period 7 years 10 months 24 days          
Business Combination, Contingent Consideration Arrangements, Weighted Average Period 5 years          
Payments for acquisition related contingent consideration $ (10,117) (5) $ (2,208)      
Line of Credit, Maturing September 17, 2024 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Long-term Debt   2,641        
Revolving credit facility outstanding balance   0        
Discount on senior unsecured notes   0        
Unamortized Debt Issuance Expense   2,641        
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Discount on senior unsecured notes (1,727) (2,000)        
Unamortized Debt Issuance Expense 4,781 5,537        
1.875 Percent Ten Year Senior Unsecured Notes [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Discount on senior unsecured notes (1,438) (1,902)        
Unamortized Debt Issuance Expense 1,279 1,779        
Senior Unsecured Notes            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Unsecured senior notes, fair value 3,474,500 3,812,300        
Fair Value, Inputs, Level 1 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Carrying value of Investments in US Treasury Securities measured at amortized cost (held-to-maturity) 689,900          
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 0        
Fair value of Investments in US Treasury Securities measured at amortized cost (held-to-maturity), classified as current 688,700          
Fair Value, Inputs, Level 2 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Long-term Debt 3,177,770 3,923,347        
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 0        
Fair Value, Inputs, Level 2 [Member] | 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Long-term Debt 843,492 842,463        
Fair Value, Inputs, Level 2 [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Long-term Debt 550,733 530,269        
Fair Value, Inputs, Level 2 [Member] | Senior Unsecured Notes            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Long-term Debt $ 3,889,300 $ 4,390,500        
Fair Value, Inputs, Level 2 [Member] | Other Debt Facilities, including the senior revolving credit facility            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Other Long-term Debt | €       € 10.3 € 3.7  
v3.24.0.1
Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 40,005 $ 46,618 $ 57,996 $ 2,953
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 14,890 0    
Fair Value, Recurring [Member] | Carrying Value [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities (13,913) (11,083)    
Foreign Currency Contract, Asset, Fair Value Disclosure 1,697 2,142    
Foreign exchange derivative liabilities, net (1,763) (1,549)    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 40,005 46,618    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 14,890      
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities (13,913) (11,083)    
Foreign Currency Contract, Asset, Fair Value Disclosure 0 0    
Foreign exchange derivative liabilities, net 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 0      
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities 0 0    
Foreign Currency Contract, Asset, Fair Value Disclosure 1,697 2,142    
Foreign exchange derivative liabilities, net (1,763) (1,549)    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 0      
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities 0 0    
Foreign Currency Contract, Asset, Fair Value Disclosure 0 0    
Foreign exchange derivative liabilities, net 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 40,005 $ 46,618    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $ 14,890      
v3.24.0.1
Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Balance beginning of period $ (46,618) $ (57,996) $ (2,953)
Additions   (4,961) (57,431)
Payments (9,741) (2,562) (5,507)
Adjustments Recognized in Goodwill   12,400  
Change in fair value (included within selling, general and administrative expenses) (3,128) 1,377 (3,119)
Balance end of period (40,005) (46,618) $ (57,996)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 14,890 $ 0  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 15,930    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) $ (1,040)    
v3.24.0.1
Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Leases [Abstract]      
Operating Lease, Cost $ 47,738 $ 39,989 $ 39,516
Schedule Of Supplemental Cash Flow Information Related To Leases [Line Items]      
Operating Lease, Payments 42,597 37,488 38,970
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability $ 10,049 $ 55,016 $ 12,345
v3.24.0.1
Leases Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]    
Operating Lease, Right-of-Use Asset $ 155,083 $ 188,351
Operating Lease, Liability, Noncurrent 132,747 169,968
Operating Lease, Liability $ 165,653 $ 201,185
Operating Lease, Weighted Average Remaining Lease Term 7 years 2 months 12 days 6 years 1 month 6 days
Operating Lease, Weighted Average Discount Rate, Percent 3.80% 2.60%
Other Current Liabilities [Member]    
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]    
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Other Liabilities, Current
Other Noncurrent Liabilities [Member]    
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]    
Operating Lease, Liability, Noncurrent $ 132,747 $ 169,968
v3.24.0.1
Leases Lessee, Operating Lease, Liability, Maturity (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Operating Lease Liabilities, Maturity [Line Items]      
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months $ 40,010    
Lessee, Operating Lease, Liability, Payments, Due Year Two 31,197    
Lessee, Operating Lease, Liability, Payments, Due Year Three 24,747    
Lessee, Operating Lease, Liability, Payments, Due Year Four 21,368    
Lessee, Operating Lease, Liability, Payments, Due Year Five 17,382    
Lessee, Operating Lease, Liability, Payments, Due after Year Five 56,051    
Operating Lease, Payments 42,597 $ 37,488 $ 38,970
Lessee, Operating Lease, Liability, Payments, Due 190,755    
Lessee, Operating Lease, Liability, Undiscounted Excess Amount (25,102)    
Operating Lease, Liability $ 165,653 $ 201,185  
v3.24.0.1
Schedule of Sales and Operating Income from Continuing Operations by Operating Segment (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
segments
Jan. 01, 2023
USD ($)
Jan. 02, 2022
USD ($)
Schedule of Segment Reporting Information, by Segment [Line Items]      
Operating income from continuing operations $ 300,562 $ 742,699 $ 1,258,457
Number of Operating Segments | segments 2    
Revenue from Contract with Customer, Excluding Assessed Tax $ 2,750,571 3,311,822 3,827,808
Interest and other expense (income), net 117,586 90,862 54,875
Income from continuing operations before income taxes 182,976 651,837 1,203,582
Asset Impairment Charges 0 0 3,868
Amortization of Intangible Assets 365,100 370,600 256,600
Acquisition and divestiture-related costs 69,200 39,800 62,800
Restructuring and other costs, net 26,601 (13,580) (14,358)
Reportable Segment Revenue [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 2,750,571 3,311,822 3,827,808
Reportable Segment Revenue [Member] | Revenue Purchase Accounting Adjustments [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax (827) (814) (2,648)
Segment Operating Income [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Reportable segment operating income (loss) 769,860 1,211,797 1,637,007
Significant litigation matters and settlements (12)   (103)
Asset Impairment Charges 0 0 (3,767)
Amortization of Intangible Assets (365,113) (370,638) (256,569)
Purchase accounting adjustments (5,956) (45,681) (40,993)
Acquisition and divestiture-related costs (69,159) (39,826) (62,760)
Significant litigation matters and settlements, Income   627  
Significant environmental matters (2,457) 0 0
Restructuring and other costs, net (26,601) (13,580) (14,358)
Diagnostics [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Reportable segment operating income (loss) 320,928 781,985 1,432,769
Revenue from Contract with Customer, Excluding Assessed Tax 1,458,231 2,018,913 2,931,939
Diagnostics [Member] | Reportable Segment Revenue [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,459,058 2,019,727 2,932,738
Discovery & Analytical Solutions [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Reportable segment operating income (loss) 489,349 503,243 281,602
Discovery & Analytical Solutions [Member] | Reportable Segment Revenue [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,292,340 1,292,909 897,718
Corporate [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Reportable segment operating income (loss) $ (40,417) $ (73,431) $ (77,364)
v3.24.0.1
Industry Segment and Geographic Area Information Schedule of Depreciation, Amortization and Capital Expenditures (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation and amortization expense $ 431,769 $ 427,000 $ 311,443
Payments to Acquire Property, Plant, and Equipment 81,368 85,632 86,020
Diagnostics [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation and amortization expense 153,099 161,394 214,178
Payments to Acquire Property, Plant, and Equipment 39,894 40,671 57,206
Corporate [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation and amortization expense 2,552 1,908 2,565
Payments to Acquire Property, Plant, and Equipment 6,139 3,429 996
All Segments [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation and amortization expense 431,769 427,000 311,443
Payments to Acquire Property, Plant, and Equipment 81,368 85,632 86,020
Life Sciences [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation and amortization expense 276,118 263,698 94,700
Payments to Acquire Property, Plant, and Equipment $ 35,335 $ 41,532 $ 27,818
v3.24.0.1
Industry Segment and Geographic Area Information Schedule of Total Assets by Segment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Schedule of Total Assets, by segment [Line Items]    
Assets $ 13,564,665 $ 14,129,855
Disposal Group, Including Discontinued Operation, Assets, Current 0 1,693,704
Diagnostics [Member]    
Schedule of Total Assets, by segment [Line Items]    
Assets 4,136,305 3,991,659
Corporate [Member]    
Schedule of Total Assets, by segment [Line Items]    
Assets 1,026,509 114,447
Life Sciences [Member]    
Schedule of Total Assets, by segment [Line Items]    
Assets $ 8,401,851 $ 8,330,045
v3.24.0.1
Industry Segment and Geographic Area Information Schedule of Revenue by Geographic Area (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Sales by Geographic Area [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax $ 2,750,571 $ 3,311,822 $ 3,827,808
UNITED STATES      
Sales by Geographic Area [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,117,654 1,546,520 1,682,294
CHINA      
Sales by Geographic Area [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 454,426 476,366 449,588
UNITED KINGDOM      
Sales by Geographic Area [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 125,419 136,017 357,911
Other International [Member]      
Sales by Geographic Area [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,053,072 1,152,919 1,338,015
Total international [Member]      
Sales by Geographic Area [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax $ 1,632,917 $ 1,765,302 $ 2,145,514
v3.24.0.1
Industry Segment and Geographic Area Information Schedule of Long-Lived Assets by Geographic Location (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 01, 2023
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets $ 758,876 $ 743,734
UNITED STATES    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 317,226 311,661
GERMANY    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 158,228 147,766
CHINA    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 59,602 68,072
Other International [Member]    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 223,820 216,235
Total international [Member]    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets $ 441,650 $ 432,073
v3.24.0.1
Quarterly Financial Information (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2023
Oct. 01, 2023
Jul. 02, 2023
Apr. 02, 2023
Jan. 01, 2023
Oct. 02, 2022
Jul. 03, 2022
Apr. 03, 2022
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Quarterly Financial Data [Abstract]                      
Restructuring and other costs, net                 $ 26,601 $ (13,580) $ (14,358)
Operating income from continuing operations                 300,562 742,699 1,258,457
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent                 513,591 56,503 53,721
Operating income from continuing operations                 179,503 512,676 889,436
Net income                 $ 693,094 $ 569,179 $ 943,157
Basic earnings per share:                      
Income from continuing operations                 $ 1.44 $ 4.06 $ 7.66
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share                 4.12 0.45 0.46
Net income                 5.56 4.51 8.12
Diluted earnings per share:                      
Income from continuing operations                 1.44 4.06 7.62
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share                 4.11 0.45 0.46
Net income                 5.55 $ 4.50 $ 8.08
Cash dividends per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28    
v3.24.0.1
Label Element Value
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents $ 402,614,000